0001615774-18-008047.txt : 20180814 0001615774-18-008047.hdr.sgml : 20180814 20180814160209 ACCESSION NUMBER: 0001615774-18-008047 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180814 DATE AS OF CHANGE: 20180814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sensus Healthcare, Inc. CENTRAL INDEX KEY: 0001494891 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 271647271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37714 FILM NUMBER: 181017243 BUSINESS ADDRESS: STREET 1: 851 BROKEN SOUND PARKWAY NW STREET 2: SUITE 215 CITY: BOCA RATON STATE: FL ZIP: 33487 BUSINESS PHONE: 561-922-5808 MAIL ADDRESS: STREET 1: 851 BROKEN SOUND PARKWAY NW STREET 2: SUITE 215 CITY: BOCA RATON STATE: FL ZIP: 33487 FORMER COMPANY: FORMER CONFORMED NAME: Sensus Healthcare, LLC DATE OF NAME CHANGE: 20100622 10-Q 1 s111751_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 001-37714

Sensus Healthcare, Inc.

(Exact name of registrant as specified in its charter)

Delaware	27-1647271
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

851 Broken Sound Pkwy., NW #215, Boca Raton, Florida	33487
(Address of principal executive office)	Zip Code)

(561) 922-5808

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an “emerging growth company”. See definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” and an “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

(Do not check if smaller

reporting company)

Emerging growth company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

As of July 31, 2018, 13,548,697 shares of the Registrant’s Common Stock, $0.01 par value, were outstanding.

SENSUS HEALTHCARE, INC.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

		Page
PART I – Financial Information

Item 1.	Condensed Consolidated Financial Statements (Unaudited)
	Balance Sheets as of June 30, 2018 and December 31, 2017	4
	Statements of Operations for the Three and Six Months Ended June 30, 2018 and 2017	5
	Statements of Stockholders’ Equity for the Six Months Ended June 30, 2018	6
	Statements of Cash Flows for the Six Months Ended June 30, 2018 and 2017	7
	Notes to the Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	19

Item 4.	Controls and Procedures	19

PART II – Other Information

Item 1.	Legal Proceedings	19

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3.	Defaults Upon Senior Securities	21

Item 4.	Mine Safety Disclosure	21

Item 5.	Other Information	21

Item 6.	Exhibits	21

Signatures		22

INTRODUCTORY NOTE

Caution Concerning Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements about our beliefs, plans, objectives, goals, expectations, estimates and intentions that are subject to significant risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. The words “may,” “could,” “should,” “would,” “will,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “target,” “goal,” and similar expressions are intended to identify forward-looking statements.

All forward-looking statements, by their nature, are subject to risks and uncertainties. Our actual future results may differ materially from those set forth in our forward-looking statements.

Our ability to achieve our financial objectives could be adversely affected by the factors discussed in detail in Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K, as well as:

●

our ability to achieve and sustain profitability;

●

market acceptance of our products;

●

our ability to successfully commercialize our products, including the SRT-100;

●

our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers;

●

the regulatory requirements applicable to us and our competitors, including any adverse regulatory action taken against us;

●

our need and ability to obtain additional financing in the future, as well as complying with the restrictions our existing revolving credit facility imposes;

●

our ability to expand, manage and maintain our direct sales and marketing organizations;

●

our actual financial results may vary significantly from forecasts and from period to period;

●

our ability to successfully develop new products, improve or enhance existing products or acquire complementary products, technologies, services or businesses;

●

our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, including the SRT-100, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties;

●

market risks regarding consolidation in the healthcare industry;

●

the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines;

●

the level and availability of government and third-party payor reimbursement for clinical procedures using our products;

●

our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel;

●

our ability to manufacture our products to meet demand;

●

our reliance on third party manufacturers and sole- or single-source suppliers;

●

our ability to reduce the per unit manufacturing cost of our products;

●

our ability to efficiently manage our manufacturing processes;

●

the regulatory and legal risks, and certain operating risks, that our international operations subject us to;

●

off label use of our products;

●

the fact that product quality issues or product defects may harm our business;

●

the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence;

●

any product liability claims;

●

limited trading in our shares and the concentration of ownership of our shares;

●

cyberattacks and other data breaches and the adverse effect on our reputation;

●

new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation;

●

the provisions in our certificate of incorporation, bylaws, or Delaware law that discourage takeovers or that limit certain disputes to be brought exclusively in the Delaware Court of Chancery;

●

the concentration of sales in our customers in the U.S. and China; and

●

our ability to manage the risk of the foregoing.

However, other factors besides those listed in Item 1A Risk Factors in our Annual Report on Form 10-K or discussed in this Form 10-Q also could adversely affect our results, and you should not consider any such list of factors to be a complete set of all potential risks or uncertainties. Any forward-looking statements made by us or on our behalf speak only as of the date they are made. We do not undertake to update any forward-looking statement, except as required by applicable law.

PART I. FINANCIAL INFORMATION

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SENSUS HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	As of June 30,			As of December 31,
	2018			2017
	(unaudited)
Assets
Current Assets
Cash and cash equivalents	$	8,012,776		$	10,085,468
Accounts receivable, net		8,048,367			4,958,255
Inventories		1,568,424			1,171,383
Investment in debt securities		—			1,104,635
Prepaid and other current assets		1,158,952			566,972
Total Current Assets		18,788,519			17,886,713
Property and Equipment, Net		823,528			394,078
Patent Rights, Net		481,930			530,123
Deposits		26,836			24,272
Total Assets	$	20,120,813		$	18,835,186
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued expenses	$	4,069,133		$	4,067,894
Product warranties		114,869			146,722
Deferred revenue, current portion		761,080			652,242
Total Current Liabilities		4,945,082			4,866,858
Revolving Credit Facility		4,215,633			2,214,970
Deferred Revenue, Net of Current Portion		293,714			73,083
Total Liabilities		9,454,429			7,154,911
Commitments and Contingencies
Stockholders’ Equity
Preferred stock, 5,000,000 shares authorized and none issued and outstanding		—			—
Common stock, $0.01 par value – 50,000,000 authorized; 13,582,151 issued and 13,548,697 outstanding at June 30, 2018; 13,522,168 issued and 13,488,714 outstanding at December 31, 2017		135,821			135,221
Additional paid-in capital		23,833,713			23,181,641
Treasury stock, 33,454 shares at cost, at June 30, 2018 and December 31, 2017, respectively		(133,816	)		(133,816	)
Accumulated deficit		(13,169,334	)		(11,502,771	)
Total Stockholders’ Equity		10,666,384			11,680,275
Total Liabilities and Stockholders’ Equity	$	20,120,813		$	18,835,186

See accompanying notes to the unaudited condensed consolidated financial statements.

SENSUS HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2018			2017			2018			2017

Revenues	$	6,056,735		$	4,968,165		$	12,012,197		$	9,322,514
Cost of Sales		2,116,108			1,553,932			4,131,308			3,053,633
Gross Profit		3,940,627			3,414,232			7,880,889			6,268,881
Operating Expenses
Selling and marketing		1,960,309			2,100,983			4,175,220			4,364,464
General and administrative		913,624			919,755			2,255,876			1,962,173
Research and development		1,565,424			1,159,322			3,063,042			2,294,747
Total Operating Expenses		4,439,357			4,180,060			9,494,138			8,621,384
Loss From Operations		(498,730	)		(765,827	)		(1,613,249	)		(2,352,503	)
Other Income (Expense)
Interest income		23,590			19,491			45,612			40,675
Interest expense		(65,511	)		(17,774	)		(98,926	)		(24,415	)
Other Income (Expense), net		(41,921	)		1,717			(53,314	)		16,260
Net Loss	$	(540,651	)	$	(764,110	)	$	(1,666,563	)	$	(2,336,243	)
Net Loss per share – basic and diluted	$	(0.04	)	$	(0.06	)	$	(0.12	)	$	(0.18	)
Weighted average number of shares used in computing net loss per share – basic and diluted		13,378,276			13,222,954			13,355,044			13,221,072

See accompanying notes to the unaudited condensed consolidated financial statements.

SENSUS HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2018


	Common Stock						Additional			Treasury Stock						Accumulated
	Shares			Amount			Paid-In Capital			Shares			Amount			Deficit			Total
December 31, 2017		13,522,168		$	135,221		$	23,181,641			(33,454	)	$	(133,816	)	$	(11,502,771	)	$	11,680,275
Stock based compensation		50,000			500			683,524			—			—			—			684,024
Surrender of shares for tax withholding on stock compensation		(19,305	)		(193	)		(122,026	)		—			—			—			(122,219	)
Exercise of warrants		29,288			293			90,574												90,867
Net loss		—			—			—			—			—			(1,666,563	)		(1,666,563	)
June 30, 2018 (unaudited)		13,582,151		$	135,821			23,833,713			(33,454	)	$	(133,816	)	$	(13,169,334	)	$	10,666,384

See accompanying notes to the unaudited condensed consolidated financial statements.

SENSUS HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	For the Six Months Ended June 30,
	2018			2017
Cash Flows From Operating Activities
Net loss	$	(1,666,563	)	$	(2,336,243	)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Bad debt expense (recovery)		(13,280	)		175,615
Depreciation and amortization		233,503			191,523
Provision for product warranties		49,416			141,322
Stock based compensation		684,024			201,033
Decrease (increase) in:
Accounts receivable		(3,076,832	)		(1,861,733	)
Inventories		(555,056	)		(267,094	)
Prepaid and other current assets		(594,545	)		101,339
Increase (decrease) in:
Accounts payable and accrued expenses		1,240			802,727
Deferred revenue		329,469			(1,761	)
Product warranties		(81,269	)		(83,507	)
Total Adjustments		(3,023,330	)		(600,536	)
Net Cash Used In Operating Activities		(4,689,893	)		(2,936,779	)
Cash Flows from Investing Activities
Acquisition of property and equipment		(456,745	)		(218,931	)
Investment in debt securities - held to maturity		—			(2,120,632	)
Investments matured		1,104,635			3,300,000
Net Cash Provided By Investing Activities		647,890			960,437
Cash Flows from Financing Activities
Exercise of warrants		90,867			—
Revolving credit facility, net		2,000,663			1,447,970
Withholding taxes on stock compensation		(122,219	)		(289,285	)
Net Cash Provided By Financing Activities		1,969,311			1,158,685
Net Decrease in Cash and Cash Equivalents		(2,072,692	)		(817,657	)
Cash and Cash Equivalents – Beginning		10,085,468			5,042,477
Cash and Cash Equivalents – Ending	$	8,012,776		$	4,224,820
Supplemental Disclosure of Cash Flow Information
Interest Paid	$	98,926		$	24,415
Non Cash Investing and Financing Activities
Transfer of inventory to property and equipment	$	158,016		$	—
Transfer of property and equipment to inventory	$	—		$	35,393

See accompanying notes to the unaudited condensed consolidated financial statements.

SENSUS HEALTHCARE, INC.
NOTES TO THE FINANCIAL STATEMENTS

(unaudited)

Note 1 — Organization and Summary of Significant Accounting Policies

Description of the Business

Sensus Healthcare, Inc. (the “Company”) is a manufacturer of superficial radiation therapy devices and has established a distribution and marketing network to sell the devices to healthcare providers globally. The Company was organized on May 7, 2010 as a limited liability corporation. On January 1, 2016, the Company completed a corporate conversion pursuant to which Sensus Healthcare, Inc. succeeded to the business of Sensus Healthcare, LLC. In February 2018, the Company opened a wholly-owned subsidiary in Israel. The Company operates as one segment based at its corporate headquarters located in Boca Raton, Florida.

Basis of Presentation

The accompanying unaudited condensed financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include certain footnotes and financial presentations normally required under accounting principles generally accepted in the United States of America for complete financial statements. The interim financial information is unaudited, but reflects all normal adjustments and accruals which are, in the opinion of management, considered necessary to provide a fair presentation for the interim periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Form 10-K, filed with the SEC. The results for the six months ended June 30, 2018 are not necessarily indicative of results to be expected for the year ending December 31, 2018, any other interim periods, or any future year or period.

Principles of consolidation

The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary in Israel. All inter-company balances and transactions have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates to which it is reasonably possible that a change could occur in the near term include, inventory reserves, receivable allowances, recoverability of long lived assets and estimation of the Company’s product warranties. Actual results could differ from those estimates.

Revenue Recognition

On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” using the modified retrospective method. The adoption of this standard did not result in a significant change to the Company’s historical revenue recognition policies and there were no necessary adjustments required to retained earnings upon adoption.

Under ASC 606, a performance obligation is a promise within a contract to transfer a distinct good or service, or a series of distinct goods and services, to a customer. Revenue is recognized when performance obligations are satisfied and the customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for goods or services. Under the standard, a contract’s transaction price is allocated to each distinct performance obligation. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identifies the contracts with a customer; (ii) identifies the performance obligations within the contract, including whether they are distinct and capable of being distinct in the context of the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, the Company satisfies each performance obligation.

The Company’s revenue consists of sales of the Company’s devices and services related to maintaining and repairing the devices. The agreement for the sale of the devices and the service contract are usually signed at the same time and in some instances a service contract is signed on a stand-alone basis. Revenue for service contracts is recognized over the service contract period on a straight-line basis. The Company determined that in practice no significant discount is given on the service contract when it is offered with the device purchase as compared to when it is sold on a stand-alone basis, by comparing the median selling price of the service contract as stand-alone and the median selling price of the service contract when sold together with the device. The service level provided is identical when the service contract is purchased stand-alone or together with the device. There is no termination provision in the service contract nor any penalties in practice for cancellation of the service contract. The service contract is not considered a performance obligation until it is paid, and it does not provide a material right for a significant discount when purchased with the device. The service portion of a sales contract or a stand-alone service contract is accounted for over the period of time of the service contract only when the customer exercises the option by paying for the service contract. For the three and six months ended June 30, 2018, service contract revenue was approximately 9.2% and 8.2% of total revenues, respectively.

The Company operates in a highly-regulated environment in which regulatory approval is sometimes required prior to the customer being able to use the product, primarily in the U.S. dermatology market. In these cases, where regulatory approval is pending, revenue is deferred until such time as regulatory approval is obtained.

Deferred revenue as of June 30, 2018 and December 31, 2017 was as follows:

	As of June 30,		As of December 31,
	2018		2017
	(unaudited)
Service contracts	$	622,662	$	570,242
Deposits on products		138,418		82,000
Total deferred revenue, current portion	$	761,080	$	652,242
Service contracts, net of current portion		293,714		73,083
Total deferred revenue	$	1,054,794	$	725,325

The Company provides warranties, generally for one year, in conjunction with the sale of its product. These warranties entitle the customer to repair, replacement, or modification of the defective product subject to the terms of the respective warranty. The Company records an estimate of future warranty claims at the time the Company recognizes revenue from the sale of the product based upon management’s estimate of the future claims rate.

Shipping and handling costs are expensed as incurred and are included in cost of sales.

Segment and Geographical Information

The Company’s revenue is generated primarily from customers in the United States, which represented approximately 94% and 99% for the three months ended June 30, 2018 and 2017, respectively, and approximately 97% and 99% for the six months ended June 30, 2018 and 2017, respectively. A customer in the US accounted for approximately 68% and 52% of revenues for the three months ended June 30, 2018 and 2017, respectively, and approximately 71% and 52% for the six months ended June 30, 2018 and 2017, respectively, and 94% and 87% of the accounts receivable as of June 30, 2018 and December 31, 2017, respectively.

Cash and Cash Equivalents

The Company maintains its cash and cash equivalents with financial institutions which balances exceed the federally insured limits. Federally insured limits are $250,000 for deposits. As of June 30, 2018 and December 31, 2017, the Company had approximately $7,807,000 and $9,952,000, respectively in excess of federally insured limits.

For purposes of the statement of cash flows, the Company considers all highly liquid financial instruments with a maturity of three months or less when purchased to be a cash equivalent.

Investments

Short-term investments consist of investments which the Company expects to convert into cash within one year and long-term investments after one year. The Company classifies its investments in debt securities at the time of purchase as held-to-maturity and reevaluates such classification on a quarterly basis. Held-to-maturity investments consist of securities that the Company has the intent and ability to retain until maturity. These securities are carried at amortized cost plus accrued interest and consist of the following:

	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
Short-Term:
Corporate bonds	$	602,599	$	—	$	256	$	602,343
United States Treasury bonds		502,036		—		332		501,704
Total Short Term:		1,104,635		—		588		1,104,047

Total Investments December 31, 2017	$	1,104,635	$	—	$	588	$	1,104,047

There were no investments as of June 30, 2018.

Accounts Receivable

The Company does business and extends credit based on an evaluation of each customer’s financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for doubtful accounts was approximately $0 and $16,000 as of June 30, 2018 and December 31, 2017. Bad debt expense (recovery) for the three months ended June 30, 2018 and 2017 was approximately ($16,000) and $14,000, respectively, and for the six months ended June 30, 2018 and 2017 was approximately ($14,000) and $176,000, respectively.

Inventories

Inventories consist of finished product and components and are stated at the lower of cost or net realizable value, determined using the first-in-first-out method.

Earnings Per Share

Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period. The diluted net income per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period, using the treasury stock method for options and warrants, as well as unvested restricted shares. In periods when the Company has incurred a net loss, options, warrants and unvested shares are considered common share equivalents but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive. Shares were excluded as follows:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2018		2017		2018		2017
Shares		21,494		—		1,687		2,409
Stock options		33,962		—		19,991		—

Advertising Costs

Advertising and promotion expenses are charged to expense as incurred. Advertising and promotion expense included in selling expense in the accompanying statements of operations amounted to approximately $310,000 and $324,000 for the three months ended June 30, 2018 and 2017, respectively, and $832,000 and $1,057,000 for the six months ended June 30, 2018 and 2017, respectively.

Recently issued and Adopted accounting Standards

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 eliminated transaction- and industry-specific revenue recognition guidance under current GAAP and replaced it with a principle based approach for determining revenue recognition. ASU 2014-09 requires that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. In April 2016, the FASB also issued ASU 2016-10, Identifying Performance Obligations and Licensing, implementation guidance on principal versus agent, identifying performance obligations, and licensing. ASU 2016-10 is effective for reporting periods beginning after December 15, 2017. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted the new revenue recognition standard in the first quarter of 2018 using the full retrospective method. There was not a material impact to revenues as a result of applying ASC 606 for the six months ended June 30, 2018, and there have not been significant changes to the Company’s business processes, systems, or internal controls as a result of implementing the standard.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842).” The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases (FAS 13). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 1, 2018, including interim periods within those fiscal years, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption of the amendments in the update is permitted. The Company is currently evaluating the effect this standard will have on its financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718) – Scope of Modification Accounting. The amendments included in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The amendments in this update will be applied prospectively to an award modified on or after the adoption date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company adopted this standard in the first quarter of 2018 and it did not have a material impact on its financial statements.

Note 2 — Property and Equipment

	As of June 30,			As to December 31,			Estimated
	2018			2017			Useful Lives
	(unaudited)
Operations and rental equipment	$	711,924		$	542,639		3 years
Tradeshow and demo equipment		704,061			271,275		3 years
Computer equipment		106,987			94,298		3 years
		1,522,972			908,212
Less accumulated depreciation		(699,444	)		(514,134	)
Property and Equipment, Net	$	823,528		$	394,078

Depreciation expense was approximately $109,000 and $73,000, for the three months ended June 30, 2018 and 2017, respectively, and approximately $185,000 and $143,000, for the six months ended June 30, 2018 and 2017, respectively.

Note 3 — Patent Rights

	As of June 30,			As of December 31,
	2018			2017
	(unaudited)
Gross carrying amount	$	1,253,018		$	1,253,018
Less accumulated amortization		(771,088	)		(722,895	)
Patent Rights, Net		481,930			530,123

Amortization expense was approximately $24,000 for the three months ended June 30, 2018 and 2017, and approximately $48,000 for the six months ended June 30, 2018 and 2017. As of June 30, 2018, future remaining amortization expense is as follows:

Year
2018 (July 1 – December 31, 2018)	$	48,193
2019		96,386
2020		96,386
2021		96,386
2022		96,386
Thereafter		48,193
Total	$	481,930

Note 4 — Revolving Credit Facility

On March 12, 2013, the Company entered into a two-year $3 million revolving credit facility. The credit facility was amended and extended effective March 12, 2015 through May 12, 2017. The maximum borrowing was reduced to $1,500,000 and was limited by the Company’s eligible borrowing base of 80% of eligible accounts receivable. On September 21, 2016, a second amendment to the credit facility extended the facility through September 21, 2017, increased the maximum borrowing to $2,000,000 and expanded the eligible accounts receivables to include certain international receivables. The Company was not in compliance in April and May 2017 with one of its financial covenants. On June 27, 2017, the covenant defaults were waived and the agreement was amended to modify the financial covenants effective June 2017. An amendment signed on September 15, 2017 extended the maturity date of the credit line through November 19, 2017. On October 31, 2017, the Company amended its revolving credit facility to extend the maturity to October 31, 2019 and to amend the financial covenants. The availability under the amended facility will equal the lesser of the $5 million commitment amount or the borrowing base plus the $2.5 million non-formula sublimit. The borrowing base consists of 80% of eligible accounts receivable, as defined in the agreement.

Interest, at Prime plus 0.75% (5.75% at June 30, 2018) and Prime plus 1.50% on non-formula borrowings (6.50% at June 30, 2018), is payable monthly, and the outstanding principal and interest are due on the maturity date. The facility is secured by all of the Company’s assets and limits the amount of additional indebtedness, restricts the sale, disposition or transfer of assets of the Company and requires the maintenance of a certain monthly adjusted quick ratio restrictive covenant, as defined in the agreement. The Company was in compliance with its financial covenants as of June 30, 2018 and December 31, 2017. Approximately $4,216,000 was outstanding under the revolving credit facility at June 30, 2018 and $2,215,000 at December 31, 2017. The Company pays commitment fees of 0.25% per annum on the average unused portion of the line of credit.

Note 5 — Product Warranties

Changes in product warranty liability were as follows for the six months ended June 30, 2018:

Balance, beginning of period	$	146,722
Warranties accrued during the period		49,416
Payments on warranty claims		(81,269	)
Balance, end of period	$	114,869

Note 6 — Commitment and Contingencies

Operating Lease Agreements

In July 2016, the Company renewed its lease with an unrelated third party for its headquarters office. The renewal was effective September 1, 2016 and expanded the office space being occupied. The lease expires in September 2022 and lease payments increase by 3% annually. In February 2017 and January 2018, the Company signed amendments to expand further the leased office space. The Company’s Israeli subsidiary also leases office space starting in February 2018. Future minimum lease payments as of June 30, 2018 are as follows:

Year	Minimum Lease Payment
2018		106,000
2019		218,000
2020		224,000
2021		231,000
2022		177,000
Total	$	956,000

Rental expense for the three months ended June 30, 2018 and 2017 was approximately $56,000 and $46,000, respectively, and for the six months ended June 30, 2018 and 2017 was approximately $109,000 and $85,000, respectively.

Manufacturing Agreement

In July 2010, the Company entered into a three-year contract manufacturing agreement with an unrelated third party for the production and manufacture of the Company’s main product in accordance with the Company’s product specifications. The agreement renews for successive years unless either party notifies the other party in writing, at least 60 days prior to the anniversary date of this agreement that it will not renew the agreement. The Company or the manufacturer has the option to terminate the agreement with 90 days written notice. Any change in the relationship with the manufacturer could have an adverse effect on the Company’s business.

Purchases from this manufacturer totaled approximately $687,000 and $216,000 for the three months ended June 30, 2018 and 2017, respectively, and approximately $1,825,000 and $1,492,000 for the six months ended June 30, 2018 and 2017, respectively. As of June 30, 2018, and December 31, 2017 approximately $967,000 and $829,000, respectively, was due to this manufacturer, which is presented in accounts payable and accrued expenses in the accompanying balance sheets.

Legal contingencies

The Company is party to certain legal proceedings in the ordinary course of business. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and related contingencies.

In November 2015, the Company learned that the Department of Justice (the “Department”) had commenced an investigation of the billing to Medicare by a physician who had treated patients with the Company’s SRT-100. The Company received a Civil Investigative Demand from the Department seeking documents and written responses in connection with that investigation. The Company has fully cooperated with the investigation. The Department has advised the Company that it was considering expanding the investigation to determine whether the Company had any involvement in the physician’s use of certain reimbursement codes. The Company disputes that it has engaged in any wrongdoing with respect to such reimbursement claims; among other things, the Company does not submit claims for reimbursement or provide coding or billing advice to physicians. To the Company’s knowledge, the Department has made no determination as to whether the Company engaged in any wrongdoing, or whether to pursue any legal action against the Company. Should the Department decide to pursue legal action, the Company believes it has strong and meritorious defenses and will vigorously defend itself. At this time, the Company is unable to estimate the cost associated with this matter.

Note 7 — Employee Benefit Plans

We sponsor a 401(k) defined contribution retirement plan that allows eligible employees to contribute a portion of their compensation through payroll deductions in accordance with specified plan guidelines. We make contributions to the plans that include matching a percentage of the employees’ contributions up to certain limits. Expenses related to this plan totaled approximately $24,000 and $0 for the three months ended June 30, 2018 and 2017, respectively, and approximately $48,000 and $0 for the six months ended June 30, 2018 and 2017, respectively.

Note 8 — Stockholders’ Equity

The Company has authorized 50,000,000 shares of common stock, of which 13,582,151 were issued and 13,548,697 outstanding at June 30, 2018; 13,522,168 shares were issued and 13,488,714 were outstanding as of December 31, 2017.

Stock Issuances

On January 1, 2016, Sensus Healthcare, LLC converted into a Delaware corporation pursuant to a statutory conversion and changed its name to Sensus Healthcare, Inc. As a result of the corporate conversion, the holders of the different classes of units of Sensus Healthcare, LLC became holders of common stock of Sensus Healthcare, Inc. Holders of warrants and options, respectively, to purchase membership interests of Sensus Healthcare, LLC became holders of warrants and options to purchase common stock of Sensus Healthcare, Inc., respectively. Each membership interest converted to one share of common stock.

Warrants

In April 2013, the closing date of the second common offering, the Company’s placement agent received investor rights to 5 year warrants to purchase 86,376 common shares of the Company at an exercise price of $4.55 per unit, which was equal to 110% of the offering price. During the first quarter of 2018, 73,309 of the warrants were exercised, and 13,067 warrants expired.

In June 2016, from the Company’s IPO, the investors received three-year warrants to purchase 2,300,000 shares of common stock at an exercise price of $6.75 per share; the warrants are exercisable through June 2, 2019. Following the first anniversary of the date of issuance, if certain conditions are met, the Company may redeem any and all of the outstanding warrants at a price equal to $0.01 per warrant.

In addition, the underwriter’s representatives for the IPO received four-year warrants to purchase up to 138,000 units, consisting of one share of common stock and one warrant to purchase one share of common stock. The warrants for the units are exercisable between June 2, 2017 and June 2, 2021 at an exercise price of $6.75 per unit.

The following table summarizes the Company’s warrant activity:

	Common Unit Warrants
		Number of Warrants			Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (In Years)
Outstanding – December 31, 2017		2,524,376		$	6.67	1.50
Granted		—			—	—
Exercised		(73,309	)		4.55	—
Expired		(13,067	)		4.55	—
Outstanding – June 30, 2018		2,438,000		$	6.75	1.05
Exercisable – June 30, 2018		2,438,000		$	6.75	1.05

The intrinsic value of the common stock warrants was approximately $1,243,000 and $19,000 as of June 30, 2018, and December 31, 2017, respectively.

2016 and 2017 equity incentive Plans

The Company has limited the aggregate number of shares of common stock to be awarded under the 2016 Equity Incentive Plan to 397,473 shares and no more than 397,473 shares of common stock in the aggregate may be granted in connection with incentive stock options. The Company has limited the aggregate number of shares of common stock to be awarded under the 2017 Equity Incentive Plan to 500,000 shares and no more than 500,000 shares of common stock in the aggregate may be granted in connection with incentive stock options. In addition, unless the Compensation Committee specifically determines otherwise, the maximum number of shares available under the 2016 and 2017 Plans and the awards granted under those plans will be subject to appropriate adjustment in the case of any stock dividends, stock splits, recapitalizations, reorganizations, mergers, consolidations, exchanges or other changes in capitalization affecting our common stock.

On June 2, 2016, 307,666 shares of restricted stock were issued to employees and were recorded at the fair value of $5.25 as per the initial offering price. In addition, on January 20, 2017, 10,000 shares of restricted stock were issued to one employee and were recorded at the fair value of $4.99 per share. The restricted shares vest 25% per year over a four-year vesting period and are being recognized as expense on a straight-line basis over the vesting period of the awards.

On January 25, 2018, 80,000 fully vested shares were granted to the nonemployee directors, and 229,334 stock options with a four-year vesting period were granted to employees. The shares were recorded at the fair value of $5.55 per share for a total of $444,000 and the stock options were valued using a Black Scholes model at $3.52 per option using the assumptions noted in the following table.

	2018
Expected volatility	67.8	%
Risk-free interest rate	2.5	%
Expected life	6.25	years
Dividend yield	0.0	%

The Company recognizes forfeitures as they occur rather than estimating a forfeiture rate. The reduction of stock compensation expense related to the forfeitures was approximately $39,000 and $7,000 for the six months ended June 30, 2018 and 2017, respectively.

A summary of the restricted stock activity is presented as follows:

	Shares			Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2017		237,000		$	5.24
Granted		—			—
Vested		(68,166	)		5.24
Forfeited		(30,000	)		5.25
Unvested balance at June 30, 2018		138,834		$	5.24

The following table summarizes the Company’s stock option activity:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)
Outstanding – December 31, 2017	—		$	—	—
Granted		229,334		3.52		4.00
Exercised		—		—		—
Expired		—		—		—
Outstanding – June 30, 2018		229,334	$	3.52		3.58
Exercisable – June 30, 2018		—		—		—

The intrinsic value of the stock options was approximately $392,000 and $0 as of June 30, 2018, and December 31, 2017, respectively.

Stock compensation expense of approximately $142,000 and $97,000 was recognized for the three months ended June 30, 2018 and 2017, respectively, and approximately $684,000 and $201,000 for the six months ended June 30, 2017, respectively. Unrecognized stock compensation expense was approximately $1,441,000 as of June 30, 2018, which will be recognized over the remaining vesting period. As of June 30, 2018, no shares were available to be granted under the 2016 Plan and 305,473 shares were available to be granted under the 2017 Plan.

Treasury Stock

The Company accounts for purchases of treasury stock under the cost method with the cost of such share purchases reflected in treasury stock in the accompanying condensed balance sheet. As of June 30, 2018, the Company had 33,454 treasury shares.

Note 9 — Income Taxes

Book income before taxes was negative for the three and six months ended June 30, 2018. Tax expense for the three and six months ended June 30, 2018 and 2017 was $0.

There are no uncertain tax positions that would require recognition in the financial statements. If the Company incurs an income tax liability in the future, interest on any income tax liability would be reported as interest expense and penalties on any income tax liability would be reported as income taxes. The Company’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analyses of tax laws, regulations and interpretations thereof as well as other factors.

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim period, disclosure and transition.

As of June 30, 2018, the Company has U.S. federal and certain state tax returns subject to examination, beginning with those filed for the year 2014.

Note 10 — Subsequent Events

The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the financial statements were issued for potential recognition or disclosure. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis in conjunction with the information set forth within the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2017 (“Annual Report”). The statements in this discussion regarding our expectations of our future performance, liquidity and capital resources, our plans, estimates, beliefs and expectations that involve risks and uncertainties, and other non-historical statements in this discussion, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “could,” “should,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “target,” “goal,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Our actual results may differ materially from those contained in or implied by any forward-looking statements. Please see the Introductory Note and Item 1A. Risk Factors of our Annual Report, as updated in our subsequent quarterly reports filed on Form 10-Q, and in our other filings made from time to time with the SEC after the date of this report.

Overview

The Company was formed in 2010 to design, manufacture and market proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. In February 2018, the Company opened a subsidiary in Israel.

The SRT-100 is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 may be used to treat primary lesions that would otherwise be difficult to treat or require extensive surgery involving sensitive areas of the head and neck regions, such as the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear, which could lead to a less than desirable cosmetic outcome. Superficial radiation therapy treatment procedures do not require the use of anesthetics and eliminates the need for skin grafting. The SRT-100 provides healthcare providers and patients with a safe, virtually painless, and substantially non-scarring treatment option for non-melanoma skin cancer and other skin conditions, such as keloids. It allows dermatologists to retain non-melanoma skin cancer patients, rather than referring them to specialists, while offering radiation oncologists an alternative to costly linear accelerator–based treatments with a process that is less invasive, more time-efficient, and improves practice economics. Our revenue is primarily derived from sales of our SRT-100 product line, which includes the SRT-100 Vision that offers additional features most notably high-frequency ultrasound for imaging.

Components of our results of operations

We manage our business globally within one reportable segment, which is consistent with how our management reviews our business, prioritizes investment and resource allocation decisions and assesses operating performance.

Results of Operations

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2018			2017			2018			2017

Revenues	$	6,056,735		$	4,968,165		$	12,012,197		$	9,322,514
Cost of Sales		2,116,108			1,553,932			4,131,308			3,053,633
Gross Profit		3,940,627			3,414,232			7,880,889			6,268,881
Operating Expenses
Selling and marketing		1,960,309			2,100,983			4,175,220			4,364,464
General and administrative		913,624			919,755			2,255,876			1,962,173
Research and development		1,565,424			1,159,322			3,063,042			2,294,747
Total Operating Expenses		4,439,357			4,180,060			9,494,138			8,621,384
Loss From Operations		(498,730	)		(765,827	)		(1,613,249	)		(2,352,503	)
Other Income (Expense)
Interest income		23,590			19,491			45,612			40,675
Interest expense		(65,511	)		(17,774	)		(98,926	)		(24,415	)
Other Income (Expense), net		(41,921	)		1,717			(53,314	)		16,260
Net Loss	$	(540,651	)	$	(764,110	)	$	(1,666,563	)	$	(2,336,243	)

Three months ended June 30, 2018 compared to the three months ended June 30, 2017

Revenue. Revenue was $6,056,735 for the three months ended June 30, 2018 compared to $4,968,165 for the three months ended June 30, 2017, an increase of $1,088,570, or 21.9%. The growth in revenue was primarily attributable to an increase in sales of the higher priced SRT-100 Vision product in the current quarter.

Cost of sales. Cost of sales was $2,116,108 for the three months ended June 30, 2018 compared to $1,553,932 for the three months ended June 30, 2017, an increase of $562,176, or 36.2%. The increase in cost was due to the increase in sales.

Gross profit. Gross profit was $3,940,627 for the three months ended June 30, 2018 compared to $3,414,232 for the three months ended June 30, 2017, an increase of $526,395, or 15.4%. Our overall gross profit percentage was 65.1% in the three months ended June 30, 2018 compared to 68.7% in the corresponding period in 2017. The decrease in gross margin percentage was primarily due to a decrease in the average selling price.

Selling and marketing. Selling and marketing expense was $1,960,309 for the three months ended June 30, 2018 compared to $2,100,983 for the three months ended June 30, 2017, a decrease of $140,675, or 6.7%. The decrease was primarily attributable to lower spending on marketing activities.

General and administrative. General and administrative expense was $913,624 for the three months ended June 30, 2018 compared to $919,755 for the three months ended June 30, 2017, a decrease of $6,132, or 0.7%.

Research and development. Research and development expense was $1,565,424 for the three months ended June 30, 2018 compared to $1,159,322 for the three months ended June 30, 2017, an increase of $406,103, or 35.0%. The increase in research and development spending was primarily attributable to the continuation and acceleration of R&D projects.

Other income (expense). We incur interest expense in connection with our secured credit facility with Silicon Valley Bank and interest income from our investment in held-to-maturity securities. Interest expense increased in 2018 with the increase in borrowings on the line of credit.

Six months ended June 30, 2018 compared to the six months ended June 30, 2017

Revenue. Revenue was $12,012,197 for the six months ended June 30, 2018 compared to $9,322,514 for the six months ended June 30, 2017, an increase of $2,689,682, or 28.9%. The growth in revenue was primarily attributable to an increase in sales of the higher priced SRT-100 Vision product.

Cost of sales. Cost of sales was $4,131,308 for the six months ended June 30, 2018 compared to $3,053,633 for the six months ended June 30, 2017, an increase of $1,077,675, or 35.3%. The increase in cost was due to the increase in sales.

Gross profit. Gross profit was $7,880,889 for the six months ended June 30, 2018 compared to $6,268,881 for the six months ended June 30, 2017, an increase of $1,612,007, or 25.7%. Our overall gross profit percentage was 65.6% in the six months ended June 30, 2018 compared to 67.2% in the corresponding period in 2017. The decrease in gross margin percentage was primarily due to the decrease in average selling price.

Selling and marketing. Selling and marketing expense was $4,175,220 for the six months ended June 30, 2018 compared to $4,364,464 for the six months ended June 30, 2017, a decrease of $189,244, or 4.3%. The decrease was primarily attributable to lower spending on marketing activities.

General and administrative. General and administrative expense was $2,255,876 for the six months ended June 30, 2018 compared to $1,962,173 for the six months ended June 30, 2017, an increase of $293,703, or 15.0%. The net increase was due primarily to a non-recurring stock compensation expense of $444,000, offset by a decrease in bad debt expense and professional fees.

Research and development. Research and development expense was $3,063,042 for the six months ended June 30, 2018 compared to $2,294,747 for the six months ended June 30, 2017, an increase of $768,295, or 33.5%. The increase in research and development spending was primarily attributable to continuation and acceleration of R&D projects.

Financial Condition

Our cash, cash equivalent and investment balance decreased from $11.2 million at December 31, 2017 to $8.0 million at June 30, 2018, primarily as a result of the operating loss of $1.7 million during the six months ended in June 30, 2018 as well as the increase in accounts receivable as a result of higher sales and longer payment terms to certain customers.

Borrowings under the revolving line of credit as of June 30, 2018 were approximately $4.2 million, an increase of $2.0 million since December 31, 2017.

Liquidity and Capital Resources

Overview

Our liquidity position and capital requirements may be impacted by a number of factors, including the following:

	●	our ability to generate and increase revenue;
	●	fluctuations in gross margins, operating expenses and net results; and
	●	fluctuations in working capital.

Our primary short-term capital needs, which are subject to change, include expenditures related to:

	●	expansion of our sales, marketing and distribution activities; and
	●	expansion of our research and development activities.

We regularly evaluate our cash requirements for current operations, commitments, capital requirements and business development transactions, and we may elect to raise additional funds for these purposes in the future.

Cash flows

The following table provides a summary of our cash flows for the periods indicated:

	For the Six Months Ended June 30,
	(unaudited)
	2018			2017
Net Cash Provided by (Used In):
Operating Activities	$	(4,689,893	)	$	(2,936,779	)
Investing Activities		647,890			960,437
Financing Activities		1,969,311			1,158,685
Total	$	(2,072,692	)	$	(817,657	)

Cash flows from operating activities

Net cash used in operating activities was $4,689,893 for the six months ended June 30, 2018, consisting of a net loss of $1,666,563 and an increase in net operating assets of $3,9764,993, partially offset by non-cash charges of $953,664. The increase in net operating assets was primarily due to the increase in accounts receivable from higher sales and longer payment terms to certain customers, increase in inventories and prepaid and other current assets as well as an increase in deferred revenue. Non-cash charges consisted of stock compensation expense, depreciation and amortization, bad debts and warranty provision. Net cash used in operating activities was $2,936,779 for the six months ended June 30, 2017, primarily due to the increase in accounts receivable and inventories as well as an increase in accounts payable and accrued expenses.

Cash flows from investing activities

Net cash provided by investing activities was $647,890 due to the maturity of debt securities held-to-maturity for $1,104,635, offset by $456,745 for the acquisition of property and equipment during the six months ended June 30, 2018. Net cash provided by investing activities was $960,437 for the six months ended June 30, 2017 maturity of debt securities held-to-maturity of $3,300,000, offset by the purchase of debt securities held-to-maturity for $2,120,632 and $218,931 for acquisition of property and equipment.

Cash flows from financing activities

Net cash provided by financing activities was $1,969,311 during the six months ended June 30, 2018, mostly from the $2,000,663 borrowing from our revolving credit facility. Net cash provided by financing activities was $1,158,685 during the six months ended June 30, 2017, mainly from $1,447,970 in borrowing from our revolving credit facility.

Indebtedness

Silicon Valley Bank Secured Credit Facility

Off-Balance Sheet Arrangements

We did not have during the periods presented, and do not currently have, any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S., or GAAP. We have identified certain accounting policies as critical to understanding our financial condition and results of our operations. For a detailed discussion on the application of these and other accounting policies, see the notes to our financial statements and our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, for the year ended December 31, 2017.

JOBS Act

We qualify as an “emerging growth company” pursuant to the provisions of the JOBS Act. For as long as we are an “emerging growth company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, reduced disclosure obligations relating to the presentation of financial statements in Management’s Discussion and Analysis of Financial Condition and Results of Operations, exemptions from the requirements of holding advisory “say-on-pay” votes on executive compensation and shareholder advisory votes on golden parachute compensation. We have availed ourselves of the reduced reporting obligations in this Quarterly Report on Form 10-Q, and expect to continue to avail ourselves of the reduced reporting obligations available to emerging growth companies in future filings.

In addition, an emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we have chosen to “opt out” of such extended transition period, and as a result, we plan to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

Item 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Control and Procedures

As of June 30, 2018, the end of the period covered by this Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that, as of June 30, 2018, the end of the period covered by this Form 10-Q, we maintained effective disclosure controls and procedures.

Changes in Internal Control over Financial Reporting

Our management, including the Chief Executive Officer and Chief Financial Officer, has reviewed our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). There have been no significant changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

Item 1A.

Risk Factors

An investment in our securities involves risks. You should carefully consider the risk factors as previously disclosed in our Form 10-K filed with the SEC for the year ended December 31, 2017, as updated in our subsequent quarterly reports, together with the other information in this Quarterly Report on Form 10-Q, including the financial statements and related notes, before deciding whether to purchase, hold, or sell our securities. The occurrence of any of these risks could harm our business, financial condition, or results of operations or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. There have been no material changes to the risk factors as previously disclosed in our Form 10-K filed with the SEC for the year ended December 31, 2017, the discussion of which is specifically incorporated by reference into this Quarterly Report on Form 10-Q.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

(a) Sales of Unregistered Securities

There were no unregistered sales of securities during the three months ended June 30, 2018.

(b) Use of Proceeds from the Sale of Registered Securities

In June 2016, we completed an initial public offering, or IPO, of units consisting of one share of common stock and one warrant to purchase one share of common stock. In connection with the IPO, we issued 2,300,000 units of our common stock at a price of $5.50 per unit, including 300,000 units pursuant to the underwriters’ full exercise of their over-allotment option for an aggregate offering price of $12.65 million. The offer and sale of all of the securities in the IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-209451), which was declared effective by the SEC on June 2, 2016.

We received total net proceeds from the IPO of approximately $10.5 million after deducting underwriting discounts and commissions of approximately $0.9 million and other offering expenses of approximately $1.4 million. We have used approximately $2.6 million for the payment of dividends to former preferred investors and approximately $7.9 million to fund our operations.

There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act on June 2, 2016.

(c) Purchases of Equity Securities by the Registrant and Affiliated Purchases.

The table below summarizes the number of shares of our common stock that were withheld to satisfy the tax withholding obligations for restricted stock that vested during the three months ended June 30, 2018.

ISSUER PURCHASES OF EQUITY SECURITIES

	Total number of shares purchased		Average price paid per share		Total number of shares purchased as part of publicly announced plans or programs		Maximum number of shares that may yet be purchased under the plans or programs
April 1 – April 30, 2018		—	$	—		—		—
May 1 – May 31, 2018		—		—		—		—
June 1 – June 30, 2018		19,305		6.33		—		—
Total		19,305	$	6.33		—		—

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosure

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

Exhibit No.

Description

31.1	Certification of Joseph C. Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, Inc., Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2	Certification of Arthur Levine, Chief Financial Officer of Sensus Healthcare, Inc., Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1	Certification of Joseph C. Sardano, Chairman and Chief Executive Officer of Sensus Healthcare, Inc., Pursuant to 18 U.S.C. Section 1350.

32.2	Certification of Arthur Levine, Chief Financial Officer of Sensus Healthcare, Inc., Pursuant to 18 U.S.C. Section 1350.

101.INS	XBRL Instance Document

101.SCH	XBRL Taxonomy Extension Schema Document

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB	XBRL Taxonomy Extension Label Linkbase Document

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SENSUS HEALTHCARE, INC.

Date: August 14, 2018	/s/ Joseph C. Sardano
	Joseph C. Sardano
	Chief Executive Officer
	(Principal Executive Officer)

Date: August 14, 2018	/s/ Arthur Levine
	Arthur Levine
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 s111751_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of CEO Pursuant to Securities Exchange Act

Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Joseph C. Sardano, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of Sensus Healthcare, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

	a	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2018	/s/ Joseph C. Sardano
	Joseph C. Sardano
	Chairman and Chief Executive Officer

EX-31.2 3 s111751_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of CFO Pursuant to Securities Exchange Act

Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Arthur Levine, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of Sensus Healthcare, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

	a	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2018	/s/ Arthur Levine
	Arthur Levine
	Chief Financial Officer

EX-32.1 4 s111751_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

Certification of CEO Pursuant to 18 U.S.C. Section 1350

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certificates that:

(1) this Quarterly Report for Sensus Healthcare, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (this “Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered therein.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

/s/ Joseph C. Sardano
Joseph C. Sardano
Chairman and Chief Executive Officer

August 14, 2018

EX-32.2 5 s111751_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

Certification of CFO Pursuant to 18 U.S.C. Section 1350

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certificates that:

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered therein.

/s/ Arthur Levine
Arthur Levine
Chief Financial Officer

August 14, 2018

EX-101.INS 6 srts-20180630.xml XBRL INSTANCE FILE 0001494891 2018-01-01 2018-06-30 0001494891 2018-07-31 0001494891 2018-06-30 0001494891 2017-12-31 0001494891 us-gaap:CommonStockMember 2017-12-31 0001494891 us-gaap:TreasuryStockMember 2017-12-31 0001494891 2017-01-01 2017-06-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001494891 us-gaap:RetainedEarningsMember 2017-12-31 0001494891 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001494891 us-gaap:CommonStockMember 2018-06-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001494891 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001494891 us-gaap:TreasuryStockMember 2018-01-01 2018-06-30 0001494891 us-gaap:TreasuryStockMember 2018-06-30 0001494891 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001494891 us-gaap:RetainedEarningsMember 2018-06-30 0001494891 2017-06-30 0001494891 srts:ServiceContractsMember 2018-06-30 0001494891 srts:DepositsOnProductsMember 2018-06-30 0001494891 srts:ServiceContractsMember 2017-12-31 0001494891 srts:DepositsOnProductsMember 2017-12-31 0001494891 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2017-01-01 2017-12-31 0001494891 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2017-01-01 2017-12-31 0001494891 us-gaap:ShortTermInvestmentsMember 2017-01-01 2017-12-31 0001494891 2017-01-01 2017-12-31 0001494891 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001494891 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2017-12-31 0001494891 us-gaap:ShortTermInvestmentsMember 2017-12-31 0001494891 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001494891 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001494891 srts:TradeshowAndDemoEquipmentMember 2018-01-01 2018-06-30 0001494891 us-gaap:ComputerEquipmentMember 2018-01-01 2018-06-30 0001494891 srts:OperationsAndRentalEquipmentMember 2018-01-01 2018-06-30 0001494891 srts:OperationsAndRentalEquipmentMember 2018-06-30 0001494891 srts:TradeshowAndDemoEquipmentMember 2018-06-30 0001494891 us-gaap:ComputerEquipmentMember 2018-06-30 0001494891 srts:OperationsAndRentalEquipmentMember 2017-12-31 0001494891 srts:TradeshowAndDemoEquipmentMember 2017-12-31 0001494891 us-gaap:ComputerEquipmentMember 2017-12-31 0001494891 2013-03-01 2013-03-12 0001494891 2013-03-12 0001494891 2015-03-12 0001494891 2016-09-21 0001494891 2010-07-01 2010-07-31 0001494891 srts:CommonUnitWarrantsMember 2018-01-01 2018-03-31 0001494891 srts:CommonUnitWarrantsMember 2017-12-31 0001494891 srts:CommonUnitWarrantsMember 2018-06-30 0001494891 country:US srts:CustomerMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-06-30 0001494891 country:US 2018-01-01 2018-06-30 0001494891 country:US srts:CustomerMember us-gaap:AccountsReceivableMember 2018-01-01 2018-06-30 0001494891 country:US 2017-01-01 2017-06-30 0001494891 country:US srts:CustomerMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-06-30 0001494891 srts:EquityIncentivePlanMember us-gaap:RestrictedStockMember 2017-01-19 2017-01-20 0001494891 us-gaap:IPOMember us-gaap:InvestorMember srts:CommonUnitWarrantsMember 2016-06-29 2016-06-30 0001494891 srts:EquityIncentivePlanMember us-gaap:RestrictedStockMember 2016-06-01 2016-06-02 0001494891 srts:PlacementAgentMember us-gaap:InvestorMember srts:CommonUnitWarrantsMember 2013-04-01 2013-04-30 0001494891 srts:EquityIncentivePlanMember 2018-01-01 2018-06-30 0001494891 srts:EquityIncentivePlan1Member 2018-01-01 2018-06-30 0001494891 us-gaap:IPOMember srts:UnderwritersRepresentativesMember srts:CommonUnitWarrantsMember 2016-06-01 2016-06-30 0001494891 us-gaap:IPOMember srts:UnderwritersRepresentativesMember srts:CommonUnitWarrantsMember srt:MinimumMember 2016-06-01 2016-06-30 0001494891 us-gaap:IPOMember srts:UnderwritersRepresentativesMember srts:CommonUnitWarrantsMember srt:MaximumMember 2016-06-01 2016-06-30 0001494891 srts:EquityIncentivePlanMember 2018-06-30 0001494891 srts:EquityIncentivePlan1Member 2018-06-30 0001494891 srts:PlacementAgentMember us-gaap:InvestorMember srts:CommonUnitWarrantsMember 2013-04-30 0001494891 2018-04-01 2018-06-30 0001494891 2017-04-01 2017-06-30 0001494891 2016-12-31 0001494891 srts:SharesMember 2018-04-01 2018-06-30 0001494891 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001494891 srts:SharesMember 2017-04-01 2017-06-30 0001494891 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001494891 srts:SharesMember 2018-01-01 2018-06-30 0001494891 srts:SharesMember 2017-01-01 2017-06-30 0001494891 country:US 2018-04-01 2018-06-30 0001494891 country:US 2017-04-01 2017-06-30 0001494891 country:US srts:CustomerMember us-gaap:SalesRevenueNetMember 2018-04-01 2018-06-30 0001494891 country:US srts:CustomerMember us-gaap:SalesRevenueNetMember 2017-04-01 2017-06-30 0001494891 country:US srts:CustomerMember us-gaap:AccountsReceivableMember 2017-01-01 2017-12-31 0001494891 srts:CommonUnitWarrantsMember 2018-01-01 2018-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure srts:Segment Sensus Healthcare, Inc. 0001494891 10-Q 2018-06-30 false --12-31 No No Yes Smaller Reporting Company Q2 2018 13548697 SRTS

13522168

-33454

13582151

-33454

50000000

13582151

13522168

13548697

13488714

33454

10666384

11680275

135221

-133816

23181641

-11502771

135821

23833713

-133816

-13169334

5000000

0.01

-1666563

-2336243

-1666563

-540651

-764110

684024

500

683524

50000

90867

293

90574

29288

20120813

18835186

26836

24272

481930

530123

823528

394078

18788519

17886713

1158952

566972

1104635

1568424

1171383

8048367

4958255

9454429

7154911

293714

73083

4215633

2214970

4945082

4866858

761080

652242

622662

138418

570242

82000

114869

146722

4069133

4067894

20120813

18835186

-13169334

-11502771

13355044

13221072

13378276

13222954

-0.12

-0.18

-0.04

-0.06

-53314

16260

-41921

1717

98926

24415

65511

17774

45612

40675

23590

19491

-1613249

-2352503

-498730

-765827

9494138

8621384

4439357

4180060

3063042

2294747

1565424

1159322

2255876

1962173

913624

919755

4175220

4364464

1960309

2100983

7880889

6268881

3940627

3414232

4131308

3053633

2116108

1553932

12012197

9322514

6056735

4968165

684024

201033

142000

97000

49416

141322

233503

191523

-13280

175615

-16000

14000

594545

-101339

555056

267094

3076832

1861733

-4689893

-2936779

-3023330

-600536

-81269

-83507

329469

-1761

1240

802727

647890

960437

1104635

3300000

2120632

456745

218931

8012776

10085468

4224820

5042477

-2072692

-817657

1969311

1158685

2000663

1447970

98926

24415

Note 1 — Organization and Summary of Significant Accounting Policies   Description of the Business   Sensus Healthcare, Inc. (the “Company”) is a manufacturer of superficial radiation therapy devices and has established a distribution and marketing network to sell the devices to healthcare providers globally. The Company was organized on May 7, 2010 as a limited liability corporation. On January 1, 2016, the Company completed a corporate conversion pursuant to which Sensus Healthcare, Inc. succeeded to the business of Sensus Healthcare, LLC. In February 2018, the Company opened a wholly-owned subsidiary in Israel. The Company operates as one segment based at its corporate headquarters located in Boca Raton, Florida.   Basis of Presentation   The accompanying unaudited condensed financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include certain footnotes and financial presentations normally required under accounting principles generally accepted in the United States of America for complete financial statements. The interim financial information is unaudited, but reflects all normal adjustments and accruals which are, in the opinion of management, considered necessary to provide a fair presentation for the interim periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Form 10-K, filed with the SEC. The results for the six months ended June 30, 2018 are not necessarily indicative of results to be expected for the year ending December 31, 2018, any other interim periods, or any future year or period.   Principles of consolidation   The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary in Israel. All inter-company balances and transactions have been eliminated.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates to which it is reasonably possible that a change could occur in the near term include, inventory reserves, receivable allowances, recoverability of long lived assets and estimation of the Company’s product warranties. Actual results could differ from those estimates.   Revenue Recognition   On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” using the modified retrospective method. The adoption of this standard did not result in a significant change to the Company’s historical revenue recognition policies and there were no necessary adjustments required to retained earnings upon adoption.   Under ASC 606, a performance obligation is a promise within a contract to transfer a distinct good or service, or a series of distinct goods and services, to a customer. Revenue is recognized when performance obligations are satisfied and the customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for goods or services. Under the standard, a contract’s transaction price is allocated to each distinct performance obligation. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identifies the contracts with a customer; (ii) identifies the performance obligations within the contract, including whether they are distinct and capable of being distinct in the context of the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, the Company satisfies each performance obligation.   The Company’s revenue consists of sales of the Company’s devices and services related to maintaining and repairing the devices. The agreement for the sale of the devices and the service contract are usually signed at the same time and in some instances a service contract is signed on a stand-alone basis. Revenue for service contracts is recognized over the service contract period on a straight-line basis. The Company determined that in practice no significant discount is given on the service contract when it is offered with the device purchase as compared to when it is sold on a stand-alone basis, by comparing the median selling price of the service contract as stand-alone and the median selling price of the service contract when sold together with the device. The service level provided is identical when the service contract is purchased stand-alone or together with the device. There is no termination provision in the service contract nor any penalties in practice for cancellation of the service contract. The service contract is not considered a performance obligation until it is paid, and it does not provide a material right for a significant discount when purchased with the device. The service portion of a sales contract or a stand-alone service contract is accounted for over the period of time of the service contract only when the customer exercises the option by paying for the service contract. For the three and six months ended June 30, 2018, service contract revenue was approximately 9.2% and 8.2% of total revenues, respectively.    The Company operates in a highly-regulated environment in which regulatory approval is sometimes required prior to the customer being able to use the product, primarily in the U.S. dermatology market. In these cases, where regulatory approval is pending, revenue is deferred until such time as regulatory approval is obtained.   Deferred revenue as of June 30, 2018 and December 31, 2017 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">As of June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">As of December 31,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%">Service contracts</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">622,662</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">570,242</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Deposits on products</td> <td> </td> <td> </td> <td style="text-align: right">138,418</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">82,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Total deferred revenue, current portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">761,080</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">652,242</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Service contracts, net of current portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">293,714</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">73,083</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2pt">Total deferred revenue</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,054,794</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">725,325</td> <td style="padding-bottom: 2pt"> </td></tr> </table>   The Company provides warranties, generally for one year, in conjunction with the sale of its product. These warranties entitle the customer to repair, replacement, or modification of the defective product subject to the terms of the respective warranty. The Company records an estimate of future warranty claims at the time the Company recognizes revenue from the sale of the product based upon management’s estimate of the future claims rate.   Shipping and handling costs are expensed as incurred and are included in cost of sales.   Segment and Geographical Information   The Company’s revenue is generated primarily from customers in the United States, which represented approximately 94% and 99% for the three months ended June 30, 2018 and 2017, respectively, and approximately 97% and 99% for the six months ended June 30, 2018 and 2017, respectively. A customer in the US accounted for approximately 68% and 52% of revenues for the three months ended June 30, 2018 and 2017, respectively, and approximately 71% and 52% for the six months ended June 30, 2018 and 2017, respectively, and 94% and 87% of the accounts receivable as of June 30, 2018 and December 31, 2017, respectively.   Cash and Cash Equivalents   The Company maintains its cash and cash equivalents with financial institutions which balances exceed the federally insured limits. Federally insured limits are $250,000 for deposits. As of June 30, 2018 and December 31, 2017, the Company had approximately $7,807,000 and $9,952,000, respectively in excess of federally insured limits.   For purposes of the statement of cash flows, the Company considers all highly liquid financial instruments with a maturity of three months or less when purchased to be a cash equivalent.   Investments   Short-term investments consist of investments which the Company expects to convert into cash within one year and long-term investments after one year. The Company classifies its investments in debt securities at the time of purchase as held-to-maturity and reevaluates such classification on a quarterly basis. Held-to-maturity investments consist of securities that the Company has the intent and ability to retain until maturity. These securities are carried at amortized cost plus accrued interest and consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amortized Cost</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Gross Unrealized Gain</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Gross Unrealized Loss</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Fair Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Short-Term:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%">Corporate bonds</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">602,599</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">256</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">602,343</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">United States Treasury bonds</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">502,036</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">332</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">501,704</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Total Short Term:</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,104,635</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">588</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,104,047</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Total Investments December 31, 2017</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,104,635</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">588</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,104,047</td> <td style="padding-bottom: 2pt"> </td></tr> </table>   There were no investments as of June 30, 2018.   Accounts Receivable   The Company does business and extends credit based on an evaluation of each customer’s financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for doubtful accounts was approximately $0 and $16,000 as of June 30, 2018 and December 31, 2017. Bad debt expense (recovery) for the three months ended June 30, 2018 and 2017 was approximately ($16,000) and $14,000, respectively, and for the six months ended June 30, 2018 and 2017 was approximately ($14,000) and $176,000, respectively.   Inventories   Inventories consist of finished product and components and are stated at the lower of cost or net realizable value, determined using the first-in-first-out method.   Earnings Per Share   Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period. The diluted net income per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period, using the treasury stock method for options and warrants, as well as unvested restricted shares. In periods when the Company has incurred a net loss, options, warrants and unvested shares are considered common share equivalents but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive. Shares were excluded as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Three Months Ended  June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Six Months Ended  June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">21,494</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,687</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">2,409</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">33,962</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,991</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> </table>   Advertising Costs   Advertising and promotion expenses are charged to expense as incurred. Advertising and promotion expense included in selling expense in the accompanying statements of operations amounted to approximately $310,000 and $324,000 for the three months ended June 30, 2018 and 2017, respectively, and $832,000 and $1,057,000 for the six months ended June 30, 2018 and 2017, respectively.   Recently issued and Adopted accounting Standards   In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 eliminated transaction- and industry-specific revenue recognition guidance under current GAAP and replaced it with a principle based approach for determining revenue recognition. ASU 2014-09 requires that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. In April 2016, the FASB also issued ASU 2016-10, Identifying Performance Obligations and Licensing, implementation guidance on principal versus agent, identifying performance obligations, and licensing. ASU 2016-10 is effective for reporting periods beginning after December 15, 2017. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted the new revenue recognition standard in the first quarter of 2018 using the full retrospective method. There was not a material impact to revenues as a result of applying ASC 606 for the six months ended June 30, 2018, and there have not been significant changes to the Company’s business processes, systems, or internal controls as a result of implementing the standard.   In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842).” The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases (FAS 13). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 1, 2018, including interim periods within those fiscal years, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption of the amendments in the update is permitted. The Company is currently evaluating the effect this standard will have on its financial statements.   In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718) – Scope of Modification Accounting. The amendments included in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The amendments in this update will be applied prospectively to an award modified on or after the adoption date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company adopted this standard in the first quarter of 2018 and it did not have a material impact on its financial statements.

Note 4 — Revolving Credit Facility   On March 12, 2013, the Company entered into a two-year $3 million revolving credit facility. The credit facility was amended and extended effective March 12, 2015 through May 12, 2017. The maximum borrowing was reduced to $1,500,000 and was limited by the Company’s eligible borrowing base of 80% of eligible accounts receivable. On September 21, 2016, a second amendment to the credit facility extended the facility through September 21, 2017, increased the maximum borrowing to $2,000,000 and expanded the eligible accounts receivables to include certain international receivables. The Company was not in compliance in April and May 2017 with one of its financial covenants. On June 27, 2017, the covenant defaults were waived and the agreement was amended to modify the financial covenants effective June 2017. An amendment signed on September 15, 2017 extended the maturity date of the credit line through November 19, 2017. On October 31, 2017, the Company amended its revolving credit facility to extend the maturity to October 31, 2019 and to amend the financial covenants. The availability under the amended facility will equal the lesser of the $5 million commitment amount or the borrowing base plus the $2.5 million non-formula sublimit. The borrowing base consists of 80% of eligible accounts receivable, as defined in the agreement.   Interest, at Prime plus 0.75% (5.75% at June 30, 2018) and Prime plus 1.50% on non-formula borrowings (6.50% at June 30, 2018), is payable monthly, and the outstanding principal and interest are due on the maturity date. The facility is secured by all of the Company’s assets and limits the amount of additional indebtedness, restricts the sale, disposition or transfer of assets of the Company and requires the maintenance of a certain monthly adjusted quick ratio restrictive covenant, as defined in the agreement. The Company was in compliance with its financial covenants as of June 30, 2018 and December 31, 2017. Approximately $4,216,000 was outstanding under the revolving credit facility at June 30, 2018 and $2,215,000 at December 31, 2017. The Company pays commitment fees of 0.25% per annum on the average unused portion of the line of credit.

Note 5 — Product Warranties   Changes in product warranty liability were as follows for the six months ended June 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 87%">Balance, beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">146,722</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warranties accrued during the period</td> <td> </td> <td> </td> <td style="text-align: right">49,416</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Payments on warranty claims</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(81,269</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Balance, end of period</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">114,869</td> <td style="padding-bottom: 2pt"> </td></tr> </table>

Note 7 — Employee Benefit Plans   We sponsor a 401(k) defined contribution retirement plan that allows eligible employees to contribute a portion of their compensation through payroll deductions in accordance with specified plan guidelines. We make contributions to the plans that include matching a percentage of the employees’ contributions up to certain limits. Expenses related to this plan totaled approximately $24,000 and $0 for the three months ended June 30, 2018 and 2017, respectively, and approximately $48,000 and $0 for the six months ended June 30, 2018 and 2017, respectively.

Note 8 — Stockholders’ Equity   The Company has authorized 50,000,000 shares of common stock, of which 13,582,151 were issued and 13,548,697 outstanding at June 30, 2018; 13,522,168 shares were issued and 13,488,714 were outstanding as of December 31, 2017.   Stock Issuances   On January 1, 2016, Sensus Healthcare, LLC converted into a Delaware corporation pursuant to a statutory conversion and changed its name to Sensus Healthcare, Inc. As a result of the corporate conversion, the holders of the different classes of units of Sensus Healthcare, LLC became holders of common stock of Sensus Healthcare, Inc. Holders of warrants and options, respectively, to purchase membership interests of Sensus Healthcare, LLC became holders of warrants and options to purchase common stock of Sensus Healthcare, Inc., respectively. Each membership interest converted to one share of common stock.   Warrants   In April 2013, the closing date of the second common offering, the Company’s placement agent received investor rights to 5 year warrants to purchase 86,376 common shares of the Company at an exercise price of $4.55 per unit, which was equal to 110% of the offering price. During the first quarter of 2018, 73,309 of the warrants were exercised, and 13,067 warrants expired.   In June 2016, from the Company’s IPO, the investors received three-year warrants to purchase 2,300,000 shares of common stock at an exercise price of $6.75 per share; the warrants are exercisable through June 2, 2019. Following the first anniversary of the date of issuance, if certain conditions are met, the Company may redeem any and all of the outstanding warrants at a price equal to $0.01 per warrant.   In addition, the underwriter’s representatives for the IPO received four-year warrants to purchase up to 138,000 units, consisting of one share of common stock and one warrant to purchase one share of common stock. The warrants for the units are exercisable between June 2, 2017 and June 2, 2021 at an exercise price of $6.75 per unit.   The following table summarizes the Company’s warrant activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Common Unit Warrants</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 61%; text-align: center"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; border-bottom: black 1pt solid; text-align: center"> </td> <td style="width: 10%; border-bottom: black 1pt solid; text-align: center">Number of Warrants</td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; border-bottom: black 1pt solid; text-align: center"> </td> <td style="width: 10%; border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; border-bottom: black 1pt solid; text-align: center"> </td> <td style="width: 10%; border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (In Years)</td> <td style="width: 1%; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding – December 31, 2017</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,524,376</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.67</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">(73,309</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">4.55</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(13,067</td> <td>)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4.55</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding – June 30, 2018</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,438,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.75</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.05</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercisable – June 30, 2018</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,438,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.75</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.05</td> <td> </td></tr> </table>   The intrinsic value of the common stock warrants was approximately $1,243,000 and $19,000 as of June 30, 2018, and December 31, 2017, respectively.   2016 and 2017 equity incentive Plans   The Company has limited the aggregate number of shares of common stock to be awarded under the 2016 Equity Incentive Plan to 397,473 shares and no more than 397,473 shares of common stock in the aggregate may be granted in connection with incentive stock options. The Company has limited the aggregate number of shares of common stock to be awarded under the 2017 Equity Incentive Plan to 500,000 shares and no more than 500,000 shares of common stock in the aggregate may be granted in connection with incentive stock options. In addition, unless the Compensation Committee specifically determines otherwise, the maximum number of shares available under the 2016 and 2017 Plans and the awards granted under those plans will be subject to appropriate adjustment in the case of any stock dividends, stock splits, recapitalizations, reorganizations, mergers, consolidations, exchanges or other changes in capitalization affecting our common stock.   On June 2, 2016, 307,666 shares of restricted stock were issued to employees and were recorded at the fair value of $5.25 as per the initial offering price. In addition, on January 20, 2017, 10,000 shares of restricted stock were issued to one employee and were recorded at the fair value of $4.99 per share. The restricted shares vest 25% per year over a four-year vesting period and are being recognized as expense on a straight-line basis over the vesting period of the awards.   On January 25, 2018, 80,000 fully vested shares were granted to the nonemployee directors, and 229,334 stock options with a four-year vesting period were granted to employees. The shares were recorded at the fair value of $5.55 per share for a total of $444,000 and the stock options were valued using a Black Scholes model at $3.52 per option using the assumptions noted in the following table.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td> </td></tr> <tr style="background-color: #CCECFF"> <td style="vertical-align: top; width: 88%">Expected volatility</td> <td style="vertical-align: top; width: 1%; padding-left: 6pt"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">67.8</td> <td style="vertical-align: bottom; width: 3%">%</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: top">Risk-free interest rate</td> <td style="vertical-align: top; padding-left: 6pt"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2.5</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCECFF"> <td style="vertical-align: top">Expected life</td> <td style="vertical-align: top; padding-left: 6pt"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6.25</td> <td style="vertical-align: bottom"> years</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: top">Dividend yield</td> <td style="vertical-align: top; padding-left: 6pt"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0.0</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td></tr> </table>   The Company recognizes forfeitures as they occur rather than estimating a forfeiture rate. The reduction of stock compensation expense related to the forfeitures was approximately $39,000 and $7,000 for the six months ended June 30, 2018 and 2017, respectively.   A summary of the restricted stock activity is presented as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted  Average Grant Date Fair Value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 73%">Unvested balance at December 31, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">237,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">5.24</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(68,166</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">5.24</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(30,000</td> <td>)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5.25</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unvested balance at June 30, 2018</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">138,834</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5.24</td> <td> </td></tr> </table>   The following table summarizes the Company’s stock option activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Options</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (In Years)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding – December 31, 2017</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 60%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">229,334</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">3.52</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">4.00</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding – June 30, 2018</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">229,334</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3.52</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3.58</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercisable – June 30, 2018</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table>   The intrinsic value of the stock options was approximately $392,000 and $0 as of June 30, 2018, and December 31, 2017, respectively.   Stock compensation expense of approximately $142,000 and $97,000 was recognized for the three months ended June 30, 2018 and 2017, respectively, and approximately $684,000 and $201,000 for the six months ended June 30, 2017, respectively. Unrecognized stock compensation expense was approximately $1,441,000 as of June 30, 2018, which will be recognized over the remaining vesting period. As of June 30, 2018, no shares were available to be granted under the 2016 Plan and 305,473 shares were available to be granted under the 2017 Plan.   Treasury Stock   The Company accounts for purchases of treasury stock under the cost method with the cost of such share purchases reflected in treasury stock in the accompanying condensed balance sheet. As of June 30, 2018, the Company had 33,454 treasury shares.

Note 9 — Income Taxes   Book income before taxes was negative for the three and six months ended June 30, 2018. Tax expense for the three and six months ended June 30, 2018 and 2017 was $0.   There are no uncertain tax positions that would require recognition in the financial statements. If the Company incurs an income tax liability in the future, interest on any income tax liability would be reported as interest expense and penalties on any income tax liability would be reported as income taxes. The Company’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analyses of tax laws, regulations and interpretations thereof as well as other factors.   The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim period, disclosure and transition.   As of June 30, 2018, the Company has U.S. federal and certain state tax returns subject to examination, beginning with those filed for the year 2014.

Note 10 — Subsequent Events   The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the financial statements were issued for potential recognition or disclosure. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Description of the Business   Sensus Healthcare, Inc. (the “Company”) is a manufacturer of superficial radiation therapy devices and has established a distribution and marketing network to sell the devices to healthcare providers globally. The Company was organized on May 7, 2010 as a limited liability corporation. On January 1, 2016, the Company completed a corporate conversion pursuant to which Sensus Healthcare, Inc. succeeded to the business of Sensus Healthcare, LLC. In February 2018, the Company opened a wholly-owned subsidiary in Israel. The Company operates as one segment based at its corporate headquarters located in Boca Raton, Florida.

Basis of Presentation   The accompanying unaudited condensed financial statements in this Quarterly Report on Form 10-Q have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. Accordingly, they do not include certain footnotes and financial presentations normally required under accounting principles generally accepted in the United States of America for complete financial statements. The interim financial information is unaudited, but reflects all normal adjustments and accruals which are, in the opinion of management, considered necessary to provide a fair presentation for the interim periods presented. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Form 10-K, filed with the SEC. The results for the six months ended June 30, 2018 are not necessarily indicative of results to be expected for the year ending December 31, 2018, any other interim periods, or any future year or period.

Principles of consolidation   The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary in Israel. All inter-company balances and transactions have been eliminated.

Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates to which it is reasonably possible that a change could occur in the near term include, inventory reserves, receivable allowances, recoverability of long lived assets and estimation of the Company’s product warranties. Actual results could differ from those estimates.

Revenue Recognition   On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” using the modified retrospective method. The adoption of this standard did not result in a significant change to the Company’s historical revenue recognition policies and there were no necessary adjustments required to retained earnings upon adoption.   Under ASC 606, a performance obligation is a promise within a contract to transfer a distinct good or service, or a series of distinct goods and services, to a customer. Revenue is recognized when performance obligations are satisfied and the customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for goods or services. Under the standard, a contract’s transaction price is allocated to each distinct performance obligation. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identifies the contracts with a customer; (ii) identifies the performance obligations within the contract, including whether they are distinct and capable of being distinct in the context of the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when, or as, the Company satisfies each performance obligation.   The Company’s revenue consists of sales of the Company’s devices and services related to maintaining and repairing the devices. The agreement for the sale of the devices and the service contract are usually signed at the same time and in some instances a service contract is signed on a stand-alone basis. Revenue for service contracts is recognized over the service contract period on a straight-line basis. The Company determined that in practice no significant discount is given on the service contract when it is offered with the device purchase as compared to when it is sold on a stand-alone basis, by comparing the median selling price of the service contract as stand-alone and the median selling price of the service contract when sold together with the device. The service level provided is identical when the service contract is purchased stand-alone or together with the device. There is no termination provision in the service contract nor any penalties in practice for cancellation of the service contract. The service contract is not considered a performance obligation until it is paid, and it does not provide a material right for a significant discount when purchased with the device. The service portion of a sales contract or a stand-alone service contract is accounted for over the period of time of the service contract only when the customer exercises the option by paying for the service contract. For the three and six months ended June 30, 2018, service contract revenue was approximately 9.2% and 8.2% of total revenues, respectively.    The Company operates in a highly-regulated environment in which regulatory approval is sometimes required prior to the customer being able to use the product, primarily in the U.S. dermatology market. In these cases, where regulatory approval is pending, revenue is deferred until such time as regulatory approval is obtained.   Deferred revenue as of June 30, 2018 and December 31, 2017 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">As of June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">As of December 31,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%">Service contracts</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">622,662</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">570,242</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Deposits on products</td> <td> </td> <td> </td> <td style="text-align: right">138,418</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">82,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Total deferred revenue, current portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">761,080</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">652,242</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Service contracts, net of current portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">293,714</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">73,083</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2pt">Total deferred revenue</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,054,794</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">725,325</td> <td style="padding-bottom: 2pt"> </td></tr> </table>   The Company provides warranties, generally for one year, in conjunction with the sale of its product. These warranties entitle the customer to repair, replacement, or modification of the defective product subject to the terms of the respective warranty. The Company records an estimate of future warranty claims at the time the Company recognizes revenue from the sale of the product based upon management’s estimate of the future claims rate.   Shipping and handling costs are expensed as incurred and are included in cost of sales.

Segment and Geographical Information   The Company’s revenue is generated primarily from customers in the United States, which represented approximately 94% and 99% for the three months ended June 30, 2018 and 2017, respectively, and approximately 97% and 99% for the six months ended June 30, 2018 and 2017, respectively. A customer in the US accounted for approximately 68% and 52% of revenues for the three months ended June 30, 2018 and 2017, respectively, and approximately 71% and 52% for the six months ended June 30, 2018 and 2017, respectively, and 94% and 87% of the accounts receivable as of June 30, 2018 and December 31, 2017, respectively.

Cash and Cash Equivalents   The Company maintains its cash and cash equivalents with financial institutions which balances exceed the federally insured limits. Federally insured limits are $250,000 for deposits. As of June 30, 2018 and December 31, 2017, the Company had approximately $7,807,000 and $9,952,000, respectively in excess of federally insured limits.   For purposes of the statement of cash flows, the Company considers all highly liquid financial instruments with a maturity of three months or less when purchased to be a cash equivalent.

Investments   Short-term investments consist of investments which the Company expects to convert into cash within one year and long-term investments after one year. The Company classifies its investments in debt securities at the time of purchase as held-to-maturity and reevaluates such classification on a quarterly basis. Held-to-maturity investments consist of securities that the Company has the intent and ability to retain until maturity. These securities are carried at amortized cost plus accrued interest and consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amortized Cost</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Gross Unrealized Gain</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Gross Unrealized Loss</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Fair Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Short-Term:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%">Corporate bonds</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">602,599</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">256</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">602,343</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">United States Treasury bonds</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">502,036</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">332</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">501,704</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Total Short Term:</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,104,635</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">588</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,104,047</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Total Investments December 31, 2017</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,104,635</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">588</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,104,047</td> <td style="padding-bottom: 2pt"> </td></tr> </table>     There were no investments as of June 30, 2018.

Accounts Receivable   The Company does business and extends credit based on an evaluation of each customer’s financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for doubtful accounts was approximately $0 and $16,000 as of June 30, 2018 and December 31, 2017. Bad debt expense (recovery) for the three months ended June 30, 2018 and 2017 was approximately ($16,000) and $14,000, respectively, and for the six months ended June 30, 2018 and 2017 was approximately ($14,000) and $176,000, respectively.

Inventories   Inventories consist of finished product and components and are stated at the lower of cost or net realizable value, determined using the first-in-first-out method.

Earnings Per Share   Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding for the period. The diluted net income per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period, using the treasury stock method for options and warrants, as well as unvested restricted shares. In periods when the Company has incurred a net loss, options, warrants and unvested shares are considered common share equivalents but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive. Shares were excluded as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Three Months Ended  June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Six Months Ended  June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">21,494</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,687</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">2,409</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">33,962</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,991</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> </table>

Advertising Costs   Advertising and promotion expenses are charged to expense as incurred. Advertising and promotion expense included in selling expense in the accompanying statements of operations amounted to approximately $310,000 and $324,000 for the three months ended June 30, 2018 and 2017, respectively, and $832,000 and $1,057,000 for the six months ended June 30, 2018 and 2017, respectively.

Recently issued and Adopted accounting Standards   In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 eliminated transaction- and industry-specific revenue recognition guidance under current GAAP and replaced it with a principle based approach for determining revenue recognition. ASU 2014-09 requires that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. In April 2016, the FASB also issued ASU 2016-10, Identifying Performance Obligations and Licensing, implementation guidance on principal versus agent, identifying performance obligations, and licensing. ASU 2016-10 is effective for reporting periods beginning after December 15, 2017. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted the new revenue recognition standard in the first quarter of 2018 using the full retrospective method. There was not a material impact to revenues as a result of applying ASC 606 for the six months ended June 30, 2018, and there have not been significant changes to the Company’s business processes, systems, or internal controls as a result of implementing the standard.   In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842).” The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases (FAS 13). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 1, 2018, including interim periods within those fiscal years, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption of the amendments in the update is permitted. The Company is currently evaluating the effect this standard will have on its financial statements.   In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718) – Scope of Modification Accounting. The amendments included in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The amendments in this update will be applied prospectively to an award modified on or after the adoption date. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company adopted this standard in the first quarter of 2018 and it did not have a material impact on its financial statements.

These securities are carried at amortized cost plus accrued interest and consist of the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amortized Cost</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Gross Unrealized Gain</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Gross Unrealized Loss</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Fair Value</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Short-Term:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%">Corporate bonds</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">602,599</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">256</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">602,343</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">United States Treasury bonds</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">502,036</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">332</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">501,704</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Total Short Term:</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,104,635</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">588</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,104,047</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Total Investments December 31, 2017</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,104,635</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">588</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,104,047</td> <td style="padding-bottom: 2pt"> </td></tr> </table>

Shares were excluded as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Three Months Ended  June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">For the Six Months Ended  June 30,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">21,494</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,687</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">2,409</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock options</td> <td> </td> <td> </td> <td style="text-align: right">33,962</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">19,991</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> </table>

As of June 30, 2018, future remaining amortization expense is as follows:    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 86%">2018 (July 1 – December 31, 2018)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">48,193</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2019</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,386</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,386</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,386</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,386</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">48,193</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2pt">Total</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">481,930</td> <td style="padding-bottom: 2pt"> </td></tr> </table>

Changes in product warranty liability were as follows for the six months ended June 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 87%">Balance, beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">146,722</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warranties accrued during the period</td> <td> </td> <td> </td> <td style="text-align: right">49,416</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Payments on warranty claims</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(81,269</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Balance, end of period</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">114,869</td> <td style="padding-bottom: 2pt"> </td></tr> </table>

Future minimum lease payments as of June 30, 2018 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Minimum Lease Payment</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 86%">2018</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">106,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2019</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">218,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">224,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">231,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">2022</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">177,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Total</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">956,000</td> <td style="padding-bottom: 2pt"> </td></tr> </table>

The following table summarizes the Company’s warrant activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Common Unit Warrants</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 61%; text-align: center"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; border-bottom: black 1pt solid; text-align: center"> </td> <td style="width: 10%; border-bottom: black 1pt solid; text-align: center">Number of Warrants</td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; border-bottom: black 1pt solid; text-align: center"> </td> <td style="width: 10%; border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 1%; border-bottom: black 1pt solid; text-align: center"> </td> <td style="width: 10%; border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (In Years)</td> <td style="width: 1%; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding – December 31, 2017</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,524,376</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.67</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.50</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">(73,309</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">4.55</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(13,067</td> <td>)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4.55</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding – June 30, 2018</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,438,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.75</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.05</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercisable – June 30, 2018</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,438,000</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">6.75</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.05</td> <td> </td></tr> </table>

The shares were recorded at the fair value of $5.55 per share for a total of $444,000 and the stock options were valued using a Black Scholes model at $3.52 per option using the assumptions noted in the following table.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td> </td></tr> <tr style="background-color: #CCECFF"> <td style="vertical-align: top; width: 88%">Expected volatility</td> <td style="vertical-align: top; width: 1%; padding-left: 6pt"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 6%; text-align: right">67.8</td> <td style="vertical-align: bottom; width: 3%">%</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr> <td style="vertical-align: top">Risk-free interest rate</td> <td style="vertical-align: top; padding-left: 6pt"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2.5</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCECFF"> <td style="vertical-align: top">Expected life</td> <td style="vertical-align: top; padding-left: 6pt"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6.25</td> <td style="vertical-align: bottom"> years</td> <td style="vertical-align: bottom"> </td></tr> <tr> <td style="vertical-align: top">Dividend yield</td> <td style="vertical-align: top; padding-left: 6pt"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">0.0</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td></tr> </table>

A summary of the restricted stock activity is presented as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted  Average Grant Date Fair Value</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 73%">Unvested balance at December 31, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">237,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">5.24</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(68,166</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">5.24</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(30,000</td> <td>)</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5.25</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unvested balance at June 30, 2018</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">138,834</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5.24</td> <td> </td></tr> </table>

The following table summarizes the Company’s stock option activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Options</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Term (In Years)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding – December 31, 2017</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 60%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">229,334</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">3.52</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">4.00</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding – June 30, 2018</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">229,334</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3.52</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3.58</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercisable – June 30, 2018</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table>

135821

135221

23833713

23181641

133816

158016 35393 -19305 -122219 -289285 -193 -122026

1054794

725325

1104635

602599

502036

1104635

256

332

588

1104047

602343

501704

1104047

19991

21494

33962

1687

2409

0.71

0.97

0.94

0.99

0.52

0.94

0.99

0.68

0.52

0.87

250000

7807000

9952000

16000

832000

1057000

310000

324000

P1Y

1522972

908212

711924

704061

106987

542639

271275

94298

699444

514134

P3Y

185000

143000

109000

73000

1253018

771088

722895

48193

96386

48193

48000

24000

P2Y

3000000

1500000

2000000

0.80

0.0075

0.0575

0.0025

On June 27, 2017, the covenant defaults were waived and the agreement was amended to modify the financial covenants effective June 2017. An amendment signed on September 15, 2017 extended the maturity date of the credit line through November 19, 2017. On October 31, 2017, the Company amended its revolving credit facility to extend the maturity to October 31, 2019 and to amend the financial covenants. The availability under the amended facility will equal the lesser of the $5 million commitment amount or the borrowing base plus the $2.5 million non-formula sublimit. The borrowing base consists of 80% of eligible accounts receivable, as defined in the agreement.

49416

81269

106000

218000

224000

231000

177000

956000

1825000

1492000

687000

216000

967000

829000

2022-09-30

0.03

109000

85000

56000

46000

P3Y

48000

24000

2524376

2438000

86376

2300000 138000 -73309 -73309 -13067 -13067 2438000

6.67

6.75

4.55

6.75 6.75 4.55 4.55 6.75 P1Y6M P1Y18D P1Y18D

0.678

0.025

P6Y2M30D

0.00

138834

237000

10000

307666

305473

68166

30000

5.24

4.99

5.24

5.25

229334

3.52

P4Y P3Y6M29D Each membership interest converted to one share of common stock. P3Y P5Y P4Y 1.10

2019-06-02

2017-06-02

2021-06-02

0.01 19000 1243000

397473

500000

P4Y

5.25

0.25

The restricted shares vest 25% per year over a four-year vesting period and are being recognized as expense on a straight-line basis over the vesting period of the awards.

1441000

39000

7000

392000

Deferred revenue as of June 30, 2018 and December 31, 2017 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">As of June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">As of December 31,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%">Service contracts</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">622,662</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">570,242</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Deposits on products</td> <td> </td> <td> </td> <td style="text-align: right">138,418</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">82,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Total deferred revenue, current portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">761,080</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">652,242</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Service contracts, net of current portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">293,714</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">73,083</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2pt">Total deferred revenue</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,054,794</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">725,325</td> <td style="padding-bottom: 2pt"> </td></tr> </table>

Note 2 — Property and Equipment   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">As of June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">As to December 31,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Estimated</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Useful Lives</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%">Operations and rental equipment</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">711,924</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">542,639</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Tradeshow and demo equipment</td> <td> </td> <td> </td> <td style="text-align: right">704,061</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">271,275</td> <td> </td> <td> </td> <td style="text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Computer equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">106,987</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">94,298</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,522,972</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">908,212</td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Less accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(699,444</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(514,134</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Property and Equipment, Net</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">823,528</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">394,078</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td></tr> </table>   Depreciation expense was approximately $109,000 and $73,000, for the three months ended June 30, 2018 and 2017, respectively, and approximately $185,000 and $143,000, for the six months ended June 30, 2018 and 2017, respectively.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">As of June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">As to December 31,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Estimated</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Useful Lives</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 61%">Operations and rental equipment</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">711,924</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">542,639</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Tradeshow and demo equipment</td> <td> </td> <td> </td> <td style="text-align: right">704,061</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">271,275</td> <td> </td> <td> </td> <td style="text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Computer equipment</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">106,987</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">94,298</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center">3 years</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,522,972</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">908,212</td> <td> </td> <td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Less accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(699,444</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(514,134</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Property and Equipment, Net</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">823,528</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">394,078</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td></tr> </table>

Note 3 — Patent Rights   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">As of June 30,</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">As of December 31,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2017</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">(unaudited)</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%">Gross carrying amount</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,253,018</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,253,018</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Less accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(771,088</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(722,895</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2pt">Patent Rights, Net</td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">481,930</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">530,123</td> <td style="padding-bottom: 2pt"> </td></tr> </table>   Amortization expense was approximately $24,000 for the three months ended June 30, 2018 and 2017, and approximately $48,000 for the six months ended June 30, 2018 and 2017. As of June 30, 2018, future remaining amortization expense is as follows:    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 86%">2018 (July 1 – December 31, 2018)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">48,193</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2019</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,386</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,386</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,386</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,386</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">48,193</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2pt">Total</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">481,930</td> <td style="padding-bottom: 2pt"> </td></tr> </table>

Note 6 — Commitment and Contingencies   Operating Lease Agreements   In July 2016, the Company renewed its lease with an unrelated third party for its headquarters office. The renewal was effective September 1, 2016 and expanded the office space being occupied. The lease expires in September 2022 and lease payments increase by 3% annually. In February 2017 and January 2018, the Company signed amendments to expand further the leased office space. The Company’s Israeli subsidiary also leases office space starting in February 2018. Future minimum lease payments as of June 30, 2018 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Year</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Minimum Lease Payment</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 86%">2018</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">106,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2019</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">218,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">224,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">231,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">2022</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">177,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2pt">Total</td> <td style="padding-bottom: 2pt"> </td> <td style="padding-bottom: 2pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">956,000</td> <td style="padding-bottom: 2pt"> </td></tr> </table>   Rental expense for the three months ended June 30, 2018 and 2017 was approximately $56,000 and $46,000, respectively, and for the six months ended June 30, 2018 and 2017 was approximately $109,000 and $85,000, respectively.   Manufacturing Agreement   In July 2010, the Company entered into a three-year contract manufacturing agreement with an unrelated third party for the production and manufacture of the Company’s main product in accordance with the Company’s product specifications. The agreement renews for successive years unless either party notifies the other party in writing, at least 60 days prior to the anniversary date of this agreement that it will not renew the agreement. The Company or the manufacturer has the option to terminate the agreement with 90 days written notice. Any change in the relationship with the manufacturer could have an adverse effect on the Company’s business.   Purchases from this manufacturer totaled approximately $687,000 and $216,000 for the three months ended June 30, 2018 and 2017, respectively, and approximately $1,825,000 and $1,492,000 for the six months ended June 30, 2018 and 2017, respectively. As of June 30, 2018, and December 31, 2017 approximately $967,000 and $829,000, respectively, was due to this manufacturer, which is presented in accounts payable and accrued expenses in the accompanying balance sheets.   Legal contingencies   The Company is party to certain legal proceedings in the ordinary course of business. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and related contingencies.   In November 2015, the Company learned that the Department of Justice (the “Department”) had commenced an investigation of the billing to Medicare by a physician who had treated patients with the Company’s SRT-100. The Company received a Civil Investigative Demand from the Department seeking documents and written responses in connection with that investigation. The Company has fully cooperated with the investigation. The Department has advised the Company that it was considering expanding the investigation to determine whether the Company had any involvement in the physician’s use of certain reimbursement codes. The Company disputes that it has engaged in any wrongdoing with respect to such reimbursement claims; among other things, the Company does not submit claims for reimbursement or provide coding or billing advice to physicians. To the Company’s knowledge, the Department has made no determination as to whether the Company engaged in any wrongdoing, or whether to pursue any legal action against the Company.  Should the Department decide to pursue legal action, the Company believes it has strong and meritorious defenses and will vigorously defend itself.  At this time, the Company is unable to estimate the cost associated with this matter.

EX-101.SCH 7 srts-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PATENT RIGHTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - REVOLVING CREDIT FACILITY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PRODUCT WARRANTIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - COMMITMENT AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PATENT RIGHTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - PRODUCT WARRANTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - COMMITMENT AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - PATENT RIGHTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - PATENT RIGHTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - PATENT RIGHTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - REVOLVING CREDIT FACILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - PRODUCT WARRANTIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENT AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COMMITMENT AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - EMPLOYEE BENEFIT PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - STOCKHOLDERS' EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - STOCKHOLDERS' EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 srts-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 srts-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 srts-20180630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Treasury Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Common Stock Additional Paid-In Capital Treasury Stock Accumulated Deficit Deferred Revenue Arrangement Type [Axis] Service Contracts [Member] Deposits on Products [Member] Investment Type [Axis] Short Term [Member] Financial Instrument [Axis] Corporate Bonds [Member] United States Treasury Bonds [Member] Antidilutive Securities [Axis] Stock options [Member] Property, Plant and Equipment, Type [Axis] Tradeshow and Demo Equipment [Member] Computer Equipment [Member] Operations and Rental Equipment [Member] Common Unit Warrants [Member] Geographical [Axis] UNITED STATES Customer [Axis] Customer [Member] Concentration Risk Benchmark [Axis] Revenue [Member] Accounts Receivable [Member] Plan Name [Axis] 2016 Equity Incentive Plan [Member] Award Type [Axis] Unvested Restricted Stock [Member] Sale of Stock [Axis] IPO [Member] Related Party [Axis] Investor [Member] Legal Entity [Axis] Placement Agent [Member] 2017 Equity Incentive Plan [Member] Underwriter's Representatives [Member] Range [Axis] Minimum [Member] Maximum [Member] Shares [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash and cash equivalents Accounts receivable, net Inventories Investment in debt securities Prepaid and other current assets Total Current Assets Property and Equipment, Net Patent Rights, Net Deposits Total Assets Liabilities and Stockholders' Equity Current Liabilities Accounts payable and accrued expenses Product warranties Deferred revenue, current portion Total Current Liabilities Revolving credit facility Deferred Revenue, Net of Current Portion Total Liabilities Commitments and Contingencies Stockholders' Equity Preferred stock, 5,000,000 shares authorized and none issued and outstanding Common stock, $0.01 par value 50,000,000 authorized; 13,582,151 issued and 13,548,697 outstanding at June 30, 2018; 13,522,168 issued and 13,488,714 outstanding at December 31, 2017 Additional paid-in capital Treasury stock, 33,454 shares at cost, at June 30, 2018 and December 31, 2017, respectively Accumulated deficit Total Stockholders' Equity Total Liabilities and Stockholders' Equity Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common Stock, outstanding Treasury stock, shares Income Statement [Abstract] Revenues Cost of Sales Gross Profit Operating Expenses Selling and marketing General and administrative Research and development Total Operating Expenses Loss From Operations Other Income (Expense) Interest income Interest expense Other Income (Expense), net Net Loss Net loss per share - basic and diluted (in dollars per share) Weighted average number of shares used in computing net loss per share - basic and diluted (in shares) Statement [Table] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance beginning Balance beginning (in shares) Stock based compensation Stock based compensation (in shares) Surrender of shares for tax withholding on stock compensation Surrender of shares for tax withholding on stock compensation (in shares) Exercise of warrants Exercise of warrants (in shares) Net loss Balance end Balance end (in shares) Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Adjustments to reconcile net (loss) to net cash and cash equivalents used in operating activities: Bad debt expense (recovery) Depreciation and amortization Provision for product warranties Stock based compensation Decrease (increase) in: Accounts receivable Inventories Prepaid and other current assets Increase (decrease) in: Accounts payable and accrued expenses Deferred revenue Product warranties Total Adjustments Net Cash Used In Operating Activities Cash Flows from Investing Activities Acquisition of property and equipment Investment in debt securities - held to maturity Investments matured Net Cash Provided By Investing Activities Cash Flows from Financing Activities Revolving credit facility, net Withholding taxes on stock compensation Net Cash Provided By Financing Activities Net Decrease in Cash and Cash Equivalents Cash and Cash Equivalents - Beginning Cash and Cash Equivalents - Ending Supplemental Disclosure of Cash Flow Information Interest Paid Non Cash Investing and Financing Activities Transfer of inventory to property and equipment Transfer of property and equipment to inventory Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] PATENT RIGHTS Debt Disclosure [Abstract] REVOLVING CREDIT FACILITY Product Warranties Disclosures [Abstract] PRODUCT WARRANTIES Commitments and Contingencies Disclosure [Abstract] COMMITMENT AND CONTINGENCIES Retirement Benefits [Abstract] EMPLOYEE BENEFIT PLANS Equity [Abstract] STOCKHOLDERS' EQUITY Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS DESCRIPTION OF THE BUSINESS BASIS OF PRESENTATION PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES REVENUE RECOGNITION SEGMENT AND GEOGRAPHICAL INFORMATION CASH AND CASH EQUIVALENTS INVESTMENTS ACCOUNTS RECEIVABLE EX-101.PRE 11 srts-20180630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Jul. 31, 2018
Document And Entity Information
Entity Registrant Name	Sensus Healthcare, Inc.
Entity Central Index Key	0001494891
Document Type	10-Q
Trading Symbol	SRTS
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,548,697
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 8,012,776	$ 10,085,468
Accounts receivable, net	8,048,367	4,958,255
Inventories	1,568,424	1,171,383
Investment in debt securities		1,104,635
Prepaid and other current assets	1,158,952	566,972
Total Current Assets	18,788,519	17,886,713
Property and Equipment, Net	823,528	394,078
Patent Rights, Net	481,930	530,123
Deposits	26,836	24,272
Total Assets	20,120,813	18,835,186
Current Liabilities
Accounts payable and accrued expenses	4,069,133	4,067,894
Product warranties	114,869	146,722
Deferred revenue, current portion	761,080	652,242
Total Current Liabilities	4,945,082	4,866,858
Revolving credit facility	4,215,633	2,214,970
Deferred Revenue, Net of Current Portion	293,714	73,083
Total Liabilities	9,454,429	7,154,911
Stockholders' Equity
Preferred stock, 5,000,000 shares authorized and none issued and outstanding
Common stock, $0.01 par value 50,000,000 authorized; 13,582,151 issued and 13,548,697 outstanding at June 30, 2018; 13,522,168 issued and 13,488,714 outstanding at December 31, 2017	135,821	135,221
Additional paid-in capital	23,833,713	23,181,641
Treasury stock, 33,454 shares at cost, at June 30, 2018 and December 31, 2017, respectively	(133,816)	(133,816)
Accumulated deficit	(13,169,334)	(11,502,771)
Total Stockholders' Equity	10,666,384	11,680,275
Total Liabilities and Stockholders' Equity	$ 20,120,813	$ 18,835,186

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	50,000,000	50,000,000
Common stock, issued	13,582,151	13,522,168
Common Stock, outstanding	13,548,697	13,488,714
Treasury stock, shares	33,454	33,454

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenues	$ 6,056,735	$ 4,968,165	$ 12,012,197	$ 9,322,514
Cost of Sales	2,116,108	1,553,932	4,131,308	3,053,633
Gross Profit	3,940,627	3,414,232	7,880,889	6,268,881
Operating Expenses
Selling and marketing	1,960,309	2,100,983	4,175,220	4,364,464
General and administrative	913,624	919,755	2,255,876	1,962,173
Research and development	1,565,424	1,159,322	3,063,042	2,294,747
Total Operating Expenses	4,439,357	4,180,060	9,494,138	8,621,384
Loss From Operations	(498,730)	(765,827)	(1,613,249)	(2,352,503)
Other Income (Expense)
Interest income	23,590	19,491	45,612	40,675
Interest expense	(65,511)	(17,774)	(98,926)	(24,415)
Other Income (Expense), net	(41,921)	1,717	(53,314)	16,260
Net Loss	$ (540,651)	$ (764,110)	$ (1,666,563)	$ (2,336,243)
Net loss per share - basic and diluted (in dollars per share)	$ (0.04)	$ (0.06)	$ (0.12)	$ (0.18)
Weighted average number of shares used in computing net loss per share - basic and diluted (in shares)	13,378,276	13,222,954	13,355,044	13,221,072

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - 6 months ended Jun. 30, 2018 - USD ($)	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Total
Balance beginning at Dec. 31, 2017	$ 135,221	$ 23,181,641	$ (133,816)	$ (11,502,771)	$ 11,680,275
Balance beginning (in shares) at Dec. 31, 2017	13,522,168		(33,454)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation	$ 500	683,524			684,024
Stock based compensation (in shares)	50,000
Surrender of shares for tax withholding on stock compensation	$ (193)	(122,026)			(122,219)
Surrender of shares for tax withholding on stock compensation (in shares)	(19,305)
Exercise of warrants	$ 293	90,574			90,867
Exercise of warrants (in shares)	29,288
Net loss				(1,666,563)	(1,666,563)
Balance end at Jun. 30, 2018	$ 135,821	$ 23,833,713	$ (133,816)	$ (13,169,334)	$ 10,666,384
Balance end (in shares) at Jun. 30, 2018	13,582,151		(33,454)

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash Flows From Operating Activities
Net loss	$ (1,666,563)	$ (2,336,243)
Adjustments to reconcile net (loss) to net cash and cash equivalents used in operating activities:
Bad debt expense (recovery)	(13,280)	175,615
Depreciation and amortization	233,503	191,523
Provision for product warranties	49,416	141,322
Stock based compensation	684,024	201,033
Decrease (increase) in:
Accounts receivable	(3,076,832)	(1,861,733)
Inventories	(555,056)	(267,094)
Prepaid and other current assets	(594,545)	101,339
Increase (decrease) in:
Accounts payable and accrued expenses	1,240	802,727
Deferred revenue	329,469	(1,761)
Product warranties	(81,269)	(83,507)
Total Adjustments	(3,023,330)	(600,536)
Net Cash Used In Operating Activities	(4,689,893)	(2,936,779)
Cash Flows from Investing Activities
Acquisition of property and equipment	(456,745)	(218,931)
Investment in debt securities - held to maturity		(2,120,632)
Investments matured	1,104,635	3,300,000
Net Cash Provided By Investing Activities	647,890	960,437
Cash Flows from Financing Activities
Exercise of warrants	90,867
Revolving credit facility, net	2,000,663	1,447,970
Withholding taxes on stock compensation	(122,219)	(289,285)
Net Cash Provided By Financing Activities	1,969,311	1,158,685
Net Decrease in Cash and Cash Equivalents	(2,072,692)	(817,657)
Cash and Cash Equivalents - Beginning	10,085,468	5,042,477
Cash and Cash Equivalents - Ending	8,012,776	4,224,820
Supplemental Disclosure of Cash Flow Information
Interest Paid	98,926	24,415
Non Cash Investing and Financing Activities
Transfer of inventory to property and equipment	158,016
Transfer of property and equipment to inventory		$ 35,393

XML 18 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 1 — Organization and Summary of Significant Accounting Policies

Description of the Business

Basis of Presentation

Principles of consolidation

Use of Estimates

Revenue Recognition

Deferred revenue as of June 30, 2018 and December 31, 2017 was as follows:

	As of June 30,		As of December 31,
	2018		2017
	(unaudited)
Service contracts	$	622,662	$	570,242
Deposits on products		138,418		82,000
Total deferred revenue, current portion	$	761,080	$	652,242
Service contracts, net of current portion		293,714		73,083
Total deferred revenue	$	1,054,794	$	725,325

Shipping and handling costs are expensed as incurred and are included in cost of sales.

Segment and Geographical Information

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid financial instruments with a maturity of three months or less when purchased to be a cash equivalent.

Investments

	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
Short-Term:
Corporate bonds	$	602,599	$	—	$	256	$	602,343
United States Treasury bonds		502,036		—		332		501,704
Total Short Term:		1,104,635		—		588		1,104,047

Total Investments December 31, 2017	$	1,104,635	$	—	$	588	$	1,104,047

There were no investments as of June 30, 2018.

Accounts Receivable

Inventories

Inventories consist of finished product and components and are stated at the lower of cost or net realizable value, determined using the first-in-first-out method.

Earnings Per Share

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2018		2017		2018		2017
Shares		21,494		—		1,687		2,409
Stock options		33,962		—		19,991		—

Advertising Costs

Recently issued and Adopted accounting Standards

XML 19 R8.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

6 Months Ended

Jun. 30, 2018

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

Note 2 — Property and Equipment

	As of June 30,			As to December 31,			Estimated
	2018			2017			Useful Lives
	(unaudited)
Operations and rental equipment	$	711,924		$	542,639		3 years
Tradeshow and demo equipment		704,061			271,275		3 years
Computer equipment		106,987			94,298		3 years
		1,522,972			908,212
Less accumulated depreciation		(699,444	)		(514,134	)
Property and Equipment, Net	$	823,528		$	394,078

XML 20 R9.htm IDEA: XBRL DOCUMENT

PATENT RIGHTS

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

PATENT RIGHTS

Note 3 — Patent Rights

	As of June 30,			As of December 31,
	2018			2017
	(unaudited)
Gross carrying amount	$	1,253,018		$	1,253,018
Less accumulated amortization		(771,088	)		(722,895	)
Patent Rights, Net		481,930			530,123

Year
2018 (July 1 – December 31, 2018)	$	48,193
2019		96,386
2020		96,386
2021		96,386
2022		96,386
Thereafter		48,193
Total	$	481,930

XML 21 R10.htm IDEA: XBRL DOCUMENT

REVOLVING CREDIT FACILITY

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

REVOLVING CREDIT FACILITY

Note 4 — Revolving Credit Facility

XML 22 R11.htm IDEA: XBRL DOCUMENT

PRODUCT WARRANTIES

6 Months Ended

Jun. 30, 2018

Product Warranties Disclosures [Abstract]

PRODUCT WARRANTIES

Note 5 — Product Warranties

Changes in product warranty liability were as follows for the six months ended June 30, 2018:

Balance, beginning of period	$	146,722
Warranties accrued during the period		49,416
Payments on warranty claims		(81,269	)
Balance, end of period	$	114,869

XML 23 R12.htm IDEA: XBRL DOCUMENT

COMMITMENT AND CONTINGENCIES

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENT AND CONTINGENCIES

Note 6 — Commitment and Contingencies

Operating Lease Agreements

Year	Minimum Lease Payment
2018		106,000
2019		218,000
2020		224,000
2021		231,000
2022		177,000
Total	$	956,000

Manufacturing Agreement

Legal contingencies

XML 24 R13.htm IDEA: XBRL DOCUMENT

EMPLOYEE BENEFIT PLANS

6 Months Ended

Jun. 30, 2018

Retirement Benefits [Abstract]

EMPLOYEE BENEFIT PLANS

Note 7 — Employee Benefit Plans

XML 25 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

STOCKHOLDERS' EQUITY

Note 8 — Stockholders’ Equity

Stock Issuances

Warrants

The following table summarizes the Company’s warrant activity:

	Common Unit Warrants
		Number of Warrants			Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (In Years)
Outstanding – December 31, 2017		2,524,376		$	6.67	1.50
Granted		—			—	—
Exercised		(73,309	)		4.55	—
Expired		(13,067	)		4.55	—
Outstanding – June 30, 2018		2,438,000		$	6.75	1.05
Exercisable – June 30, 2018		2,438,000		$	6.75	1.05

The intrinsic value of the common stock warrants was approximately $1,243,000 and $19,000 as of June 30, 2018, and December 31, 2017, respectively.

2016 and 2017 equity incentive Plans

	2018
Expected volatility	67.8	%
Risk-free interest rate	2.5	%
Expected life	6.25	years
Dividend yield	0.0	%

A summary of the restricted stock activity is presented as follows:

	Shares			Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2017		237,000		$	5.24
Granted		—			—
Vested		(68,166	)		5.24
Forfeited		(30,000	)		5.25
Unvested balance at June 30, 2018		138,834		$	5.24

The following table summarizes the Company’s stock option activity:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)
Outstanding – December 31, 2017	—		$	—	—
Granted		229,334		3.52		4.00
Exercised		—		—		—
Expired		—		—		—
Outstanding – June 30, 2018		229,334	$	3.52		3.58
Exercisable – June 30, 2018		—		—		—

The intrinsic value of the stock options was approximately $392,000 and $0 as of June 30, 2018, and December 31, 2017, respectively.

Treasury Stock

XML 26 R15.htm IDEA: XBRL DOCUMENT

INCOME TAXES

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES

Note 9 — Income Taxes

Book income before taxes was negative for the three and six months ended June 30, 2018. Tax expense for the three and six months ended June 30, 2018 and 2017 was $0.

As of June 30, 2018, the Company has U.S. federal and certain state tax returns subject to examination, beginning with those filed for the year 2014.

XML 27 R16.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

Note 10 — Subsequent Events

XML 28 R17.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

DESCRIPTION OF THE BUSINESS

Description of the Business

BASIS OF PRESENTATION

Basis of Presentation

PRINCIPLES OF CONSOLIDATION

Principles of consolidation

USE OF ESTIMATES

Use of Estimates

REVENUE RECOGNITION

Revenue Recognition

Deferred revenue as of June 30, 2018 and December 31, 2017 was as follows:

	As of June 30,		As of December 31,
	2018		2017
	(unaudited)
Service contracts	$	622,662	$	570,242
Deposits on products		138,418		82,000
Total deferred revenue, current portion	$	761,080	$	652,242
Service contracts, net of current portion		293,714		73,083
Total deferred revenue	$	1,054,794	$	725,325

Shipping and handling costs are expensed as incurred and are included in cost of sales.

SEGMENT AND GEOGRAPHICAL INFORMATION

Segment and Geographical Information

CASH AND CASH EQUIVALENTS

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid financial instruments with a maturity of three months or less when purchased to be a cash equivalent.

INVESTMENTS

Investments

	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
Short-Term:
Corporate bonds	$	602,599	$	—	$	256	$	602,343
United States Treasury bonds		502,036		—		332		501,704
Total Short Term:		1,104,635		—		588		1,104,047

Total Investments December 31, 2017	$	1,104,635	$	—	$	588	$	1,104,047

There were no investments as of June 30, 2018.

ACCOUNTS RECEIVABLE

Accounts Receivable

INVENTORIES

Inventories

Inventories consist of finished product and components and are stated at the lower of cost or net realizable value, determined using the first-in-first-out method.

EARNINGS PER SHARE

Earnings Per Share

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2018		2017		2018		2017
Shares		21,494		—		1,687		2,409
Stock options		33,962		—		19,991		—

ADVERTISING COSTS

Advertising Costs

RECENTLY ISUED ACCOUNTING PRONOUNCEMENT

Recently issued and Adopted accounting Standards

XML 29 R18.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of deferred revenue

Deferred revenue as of June 30, 2018 and December 31, 2017 was as follows:

	As of June 30,		As of December 31,
	2018		2017
	(unaudited)
Service contracts	$	622,662	$	570,242
Deposits on products		138,418		82,000
Total deferred revenue, current portion	$	761,080	$	652,242
Service contracts, net of current portion		293,714		73,083
Total deferred revenue	$	1,054,794	$	725,325

Schedule of investment

These securities are carried at amortized cost plus accrued interest and consist of the following:

	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
Short-Term:
Corporate bonds	$	602,599	$	—	$	256	$	602,343
United States Treasury bonds		502,036		—		332		501,704
Total Short Term:		1,104,635		—		588		1,104,047

Total Investments December 31, 2017	$	1,104,635	$	—	$	588	$	1,104,047

Schedule of antidilutive

Shares were excluded as follows:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2018		2017		2018		2017
Shares		21,494		—		1,687		2,409
Stock options		33,962		—		19,991		—

XML 30 R19.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

6 Months Ended

Jun. 30, 2018

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	As of June 30,			As to December 31,			Estimated
	2018			2017			Useful Lives
	(unaudited)
Operations and rental equipment	$	711,924		$	542,639		3 years
Tradeshow and demo equipment		704,061			271,275		3 years
Computer equipment		106,987			94,298		3 years
		1,522,972			908,212
Less accumulated depreciation		(699,444	)		(514,134	)
Property and Equipment, Net	$	823,528		$	394,078

XML 31 R20.htm IDEA: XBRL DOCUMENT

PATENT RIGHTS (Tables)

6 Months Ended

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

	As of June 30,			As of December 31,
	2018			2017
	(unaudited)
Gross carrying amount	$	1,253,018		$	1,253,018
Less accumulated amortization		(771,088	)		(722,895	)
Patent Rights, Net		481,930			530,123

Schedule of amortization expense

As of June 30, 2018, future remaining amortization expense is as follows:

Year
2018 (July 1 – December 31, 2018)	$	48,193
2019		96,386
2020		96,386
2021		96,386
2022		96,386
Thereafter		48,193
Total	$	481,930

XML 32 R21.htm IDEA: XBRL DOCUMENT

PRODUCT WARRANTIES (Tables)

6 Months Ended

Jun. 30, 2018

Product Warranties Disclosures [Abstract]

Schedule of changes in product warranty liability

Changes in product warranty liability were as follows for the six months ended June 30, 2018:

Balance, beginning of period	$	146,722
Warranties accrued during the period		49,416
Payments on warranty claims		(81,269	)
Balance, end of period	$	114,869

XML 33 R22.htm IDEA: XBRL DOCUMENT

COMMITMENT AND CONTINGENCIES (Tables)

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments for operating leases

Future minimum lease payments as of June 30, 2018 are as follows:

Year	Minimum Lease Payment
2018		106,000
2019		218,000
2020		224,000
2021		231,000
2022		177,000
Total	$	956,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Schedule of warrant activity

The following table summarizes the Company’s warrant activity:

	Common Unit Warrants
		Number of Warrants			Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (In Years)
Outstanding – December 31, 2017		2,524,376		$	6.67	1.50
Granted		—			—	—
Exercised		(73,309	)		4.55	—
Expired		(13,067	)		4.55	—
Outstanding – June 30, 2018		2,438,000		$	6.75	1.05
Exercisable – June 30, 2018		2,438,000		$	6.75	1.05

Schedule of Stock Options, Valuation Assumptions

The shares were recorded at the fair value of $5.55 per share for a total of $444,000 and the stock options were valued using a Black Scholes model at $3.52 per option using the assumptions noted in the following table.

	2018
Expected volatility	67.8	%
Risk-free interest rate	2.5	%
Expected life	6.25	years
Dividend yield	0.0	%

Summary of restricted stock activity

A summary of the restricted stock activity is presented as follows:

	Shares			Weighted Average Grant Date Fair Value
Unvested balance at December 31, 2017		237,000		$	5.24
Granted		—			—
Vested		(68,166	)		5.24
Forfeited		(30,000	)		5.25
Unvested balance at June 30, 2018		138,834		$	5.24

Schedule of option activity

The following table summarizes the Company’s stock option activity:

	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (In Years)
Outstanding – December 31, 2017	—		$	—	—
Granted		229,334		3.52		4.00
Exercised		—		—		—
Expired		—		—		—
Outstanding – June 30, 2018		229,334	$	3.52		3.58
Exercisable – June 30, 2018		—		—		—

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]
Total deferred revenue, current portion	$ 761,080	$ 652,242
Service contracts, net of current portion	293,714	73,083
Total deferred revenue	1,054,794	725,325
Service Contracts [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue, current portion	622,662	570,242
Deposits on Products [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue, current portion	$ 138,418	$ 82,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)	12 Months Ended
	Dec. 31, 2017 USD ($)
Amortized Cost	$ 1,104,635
Gross Unrealized Gain
Gross Unrealized Loss	588
Fair Value	1,104,047
Short Term [Member]
Amortized Cost	1,104,635
Gross Unrealized Gain
Gross Unrealized Loss	588
Fair Value	1,104,047
Short Term [Member] \| Corporate Bonds [Member]
Amortized Cost	602,599
Gross Unrealized Gain
Gross Unrealized Loss	256
Fair Value	602,343
Short Term [Member] \| United States Treasury Bonds [Member]
Amortized Cost	502,036
Gross Unrealized Gain
Gross Unrealized Loss	332
Fair Value	$ 501,704

XML 37 R26.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	21,494		1,687	2,409
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	33,962		19,991

XML 38 R27.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) Segment	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of operating segments \| Segment			1
Cash, FDIC insured amount	$ 250,000		$ 250,000
Cash uninsured amount	7,807,000		7,807,000		$ 9,952,000
Allowance for doubtful accounts receivable, current	0		0		$ 16,000
Advertising and promotion expense	310,000	$ 324,000	$ 832,000	$ 1,057,000
Product warranty term			1 year
Bad debt expense (recovery)	$ (16,000)	$ 14,000	$ (13,280)	$ 175,615
UNITED STATES
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Reveune percent	94.00%	99.00%	97.00%	99.00%
UNITED STATES \| Customer [Member] \| Revenue [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Reveune percent	68.00%	52.00%	71.00%	52.00%
UNITED STATES \| Customer [Member] \| Accounts Receivable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Reveune percent			94.00%		87.00%

XML 39 R28.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($)	6 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,522,972	$ 908,212
Less accumulated depreciation	(699,444)	(514,134)
Property and Equipment, Net	823,528	394,078
Operations and Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 711,924	542,639
Property, plant and equipment, useful Life	3 years
Tradeshow and Demo Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 704,061	271,275
Property, plant and equipment, useful Life	3 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 106,987	$ 94,298
Property, plant and equipment, useful Life	3 years

XML 40 R29.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 109,000	$ 73,000	$ 185,000	$ 143,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

PATENT RIGHTS (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Gross carrying amount	$ 1,253,018	$ 1,253,018
Less accumulated amortization	(771,088)	(722,895)
Patent Rights, Net	$ 481,930	$ 530,123

XML 42 R31.htm IDEA: XBRL DOCUMENT

PATENT RIGHTS (Details 1) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets, Net [Abstract]
2018 (July 1- December 31, 2018)	$ 48,193
2019	96,386
2020	96,386
2021	96,386
2022	96,386
Thereafter	48,193
Patent Rights, Net	$ 481,930	$ 530,123

XML 43 R32.htm IDEA: XBRL DOCUMENT

PATENT RIGHTS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
PATENT RIGHTS (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 24,000	$ 24,000	$ 48,000	$ 48,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

REVOLVING CREDIT FACILITY (Details Narrative) - USD ($)		6 Months Ended
REVOLVING CREDIT FACILITY (Details Narrative) - USD ($)	Mar. 12, 2013	Jun. 30, 2018	Dec. 31, 2017	Sep. 21, 2016	Mar. 12, 2015
Debt Disclosure [Abstract]
Debt instrument, term	2 years
Line of credit facility, maximum borrowing capacity	$ 3,000,000			$ 2,000,000	$ 1,500,000
Line of credit percentage of borrowing base to accounts receivables	80.00%
Debt instrument, basis spread on variable rate		0.75%
Debt instrument, interest rate, effective percentage		5.75%
Line of credit, outstanding		$ 4,215,633	$ 2,214,970
Line of credit facility, unused capacity, commitment fee percentage		0.25%
Line of credit description		On June 27, 2017, the covenant defaults were waived and the agreement was amended to modify the financial covenants effective June 2017. An amendment signed on September 15, 2017 extended the maturity date of the credit line through November 19, 2017. On October 31, 2017, the Company amended its revolving credit facility to extend the maturity to October 31, 2019 and to amend the financial covenants. The availability under the amended facility will equal the lesser of the $5 million commitment amount or the borrowing base plus the $2.5 million non-formula sublimit. The borrowing base consists of 80% of eligible accounts receivable, as defined in the agreement.

- Definition

The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 45 R34.htm IDEA: XBRL DOCUMENT

PRODUCT WARRANTIES (Details)	6 Months Ended
PRODUCT WARRANTIES (Details)	Jun. 30, 2018 USD ($)
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance, beginning of period	$ 146,722
Warranties accrued during the period	49,416
Payments on warranty claims	(81,269)
Balance, end of period	$ 114,869

XML 46 R35.htm IDEA: XBRL DOCUMENT

COMMITMENT AND CONTINGENCIES (Details)	Jun. 30, 2018 USD ($)
Operating Leases, Future Minimum Payments Due [Abstract]
2018 (July 1- December 31, 2018)	$ 106,000
2019	218,000
2020	224,000
2021	231,000
2022	177,000
Total	$ 956,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

COMMITMENT AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2010	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Payments to suppliers		$ 687,000	$ 216,000	$ 1,825,000	$ 1,492,000
Accounts payable and accrued expenses		967,000		$ 967,000		$ 829,000
Lease expiration date				Sep. 30, 2022
Percentage of increase in lease payments				3.00%
Rental expense		$ 56,000	$ 46,000	$ 109,000	$ 85,000
Manufacturing agreement contract term	3 years

XML 48 R37.htm IDEA: XBRL DOCUMENT

EMPLOYEE BENEFIT PLANS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
EMPLOYEE BENEFIT PLANS (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Retirement Benefits [Abstract]
Expenses related to employee benefit plan	$ 24,000	$ 0	$ 48,000	$ 0

XML 49 R38.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details) - Common Unit Warrants [Member] - $ / shares	3 Months Ended	6 Months Ended
	Mar. 31, 2018	Jun. 30, 2018
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding at beginning	2,524,376	2,524,376
Granted
Exercised	(73,309)	(73,309)
Forfeited	(13,067)	(13,067)
Outstanding at ending		2,438,000
Exercisable at end		2,438,000
Class of Warrant or Right, Exercise Price of Warrants or Rights [Roll Forward]
Outstanding at beginning	$ 6.67	$ 6.67
Granted
Exercised		4.55
Forfeited		4.55
Outstanding at ending		6.75
Exercisable at ending		$ 6.75
Class Of Warrant Or Right Weighted Average Remaining Contract Term Of Warrants Or Rights [Roll Forward]
Outstanding at beginning		1 year 6 months
Outstanding at ending		1 year 18 days
Exercisable at ending		1 year 18 days

XML 50 R39.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 1)	6 Months Ended
STOCKHOLDERS' EQUITY (Details 1)	Jun. 30, 2018
Equity [Abstract]
Expected volatility	67.80%
Risk-free interest rate	2.50%
Expected life	6 years 2 months 30 days
Dividend yield	0.00%

XML 51 R40.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 2)	6 Months Ended
STOCKHOLDERS' EQUITY (Details 2)	Jun. 30, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested balance at beginning \| shares	237,000
Granted \| shares
Vested \| shares	(68,166)
Forfeited \| shares	(30,000)
Unvested balance at end \| shares	138,834
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Rollforward]
Unvested balance at beginning \| $ / shares	$ 5.24
Granted \| $ / shares
Vested \| $ / shares	5.24
Forfeited \| $ / shares	5.25
Unvested balance at end \| $ / shares	$ 5.24

XML 52 R41.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details 3)	6 Months Ended
STOCKHOLDERS' EQUITY (Details 3)	Jun. 30, 2018 $ / shares shares
Number of Options
Outstanding at beginning \| shares
Granted \| shares	229,334
Exercised \| shares
Expired \| shares
Outstanding at end \| shares	229,334
Exercisable at end \| shares
Weighted Average Exercise
Outstanding at beginning (in dollars per share) \| $ / shares
Granted (in dollars per share) \| $ / shares	3.52
Exercised \| $ / shares
Expired \| $ / shares
Outstanding at end (in dollars per share) \| $ / shares	3.52
Exercisable at end (in dollars per share) \| $ / shares
Granted	4 years
Outstanding at end	3 years 6 months 29 days

XML 53 R42.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)				1 Months Ended		3 Months Ended			6 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Jan. 20, 2017	Jun. 30, 2016	Jun. 02, 2016	Jun. 30, 2016	Apr. 30, 2013	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Common stock, authorized						50,000,000			50,000,000		50,000,000
Common stock, issued						13,582,151			13,582,151		13,522,168
Common stock,outstanding						13,548,697			13,548,697		13,488,714
Description of membership interest									Each membership interest converted to one share of common stock.
Stock compensation expense						$ 142,000		$ 97,000	$ 684,024	$ 201,033
Weighted average grant date fair value (in dollars per share)
Number of restricted stock granted
Unrecognized stock compensation expense											$ 1,441,000
Reduction of stock compensation expense value forfeited									$ 39,000	$ 7,000
Intrinsic value of the stock options						$ 392,000			$ 392,000		$ 0
Treasury stock						33,454			33,454		33,454
Common Unit Warrants [Member]
Number of warrant outstanding						2,438,000			2,438,000		2,524,376
Warrant exercise price (in dollars per share)						$ 6.75			$ 6.75		$ 6.67
Exercised							(73,309)		(73,309)
Forfeited							(13,067)		(13,067)
Number of warrant granted
Warrant granted exercise price (in dollars per share)
Intrinsic value of common stock warrants						$ 1,243,000			$ 1,243,000		$ 19,000
Investor [Member] \| Common Unit Warrants [Member] \| IPO [Member]
Warrant term		3 years
Number of warrant granted		2,300,000
Warrant granted exercise price (in dollars per share)		$ 6.75
Date of warrants exercisable		Jun. 02, 2019
Warrant redemption price (in dollars per warrant)		$ 0.01
Underwriter's Representatives [Member] \| Common Unit Warrants [Member] \| IPO [Member]
Warrant term				4 years
Number of warrant granted				138,000
Warrant granted exercise price (in dollars per share)				$ 6.75
Minimum [Member] \| Underwriter's Representatives [Member] \| Common Unit Warrants [Member] \| IPO [Member]
Date of warrants exercisable				Jun. 02, 2017
Maximum [Member] \| Underwriter's Representatives [Member] \| Common Unit Warrants [Member] \| IPO [Member]
Date of warrants exercisable				Jun. 02, 2021
2016 Equity Incentive Plan [Member]
Number of authorized shares under the plan						397,473			397,473
Number of restricted stock granted									0
2017 Equity Incentive Plan [Member]
Number of authorized shares under the plan						500,000			500,000
Number of restricted stock granted									305,473
Unvested Restricted Stock [Member] \| 2016 Equity Incentive Plan [Member]
Weighted average grant date fair value (in dollars per share)	$ 4.99
Vesting period			4 years
Number of restricted stock granted	10,000		307,666
Initial offering price (in dollars per share)			$ 5.25
Vesting percentage			25.00%
Description of vesting rights			The restricted shares vest 25% per year over a four-year vesting period and are being recognized as expense on a straight-line basis over the vesting period of the awards.
Placement Agent [Member] \| Investor [Member] \| Common Unit Warrants [Member]
Warrant term					5 years
Number of warrant outstanding					86,376
Warrant exercise price (in dollars per share)					$ 4.55
Percentage of offering price					110.00%

XML 54 R43.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
INCOME TAXES (Details Narrative) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Tax expense	$ 0	$ 0	$ 0	$ 0

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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